

**STANDARD CHEM. & PHARM. CO., LTD.**  
**PARENT COMPANY ONLY FINANCIAL**  
**STATEMENTS AND INDEPENDENT AUDITORS’**  
**REPORT**  
**DECEMBER 31, 2023 AND 2022**

---

For the convenience of readers and for information purpose only, the auditors’ report and the accompanying financial statements have been translated into English from the original Chinese version prepared and used in the Republic of China. In the event of any discrepancy between the English version and the original Chinese version or any differences in the interpretation of the two versions, the Chinese-language auditors’ report and financial statements shall prevail.

## INDEPENDENT AUDITORS' REPORT TRANSLATED FROM CHINESE

To the Board of Directors and Shareholders of STANDARD CHEM. & PHARM. CO., LTD.

### **Opinion**

We have audited the accompanying parent company only balance sheets of STANDARD CHEM. & PHARM. CO., LTD. (the “Company”) as of December 31, 2023 and 2022, and the related parent company only statements of comprehensive income, of changes in equity and of cash flows for the years then ended, and notes to the parent company only financial statements, including a summary of material accounting policies.

In our opinion, based on our audits and the reports of other auditors (refer to Other matter section), the accompanying parent company only financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2023 and 2022, and its financial performance and its cash flows for the years then ended in accordance with the Regulations Governing the Preparation of Financial Reports by Securities Issuers.

### **Basis for opinion**

We conducted our audits in accordance with the Regulations Governing Financial Statement Audit and Attestation Engagements of Certified Public Accountants and Standards on Auditing of the Republic of China. Our responsibilities under those standards are further described in the Auditors' responsibilities for the audit of the parent company only financial statements section of our report. We are independent of the Company in accordance with the Norm of Professional Ethics for Certified Public Accountant of the Republic of China, and we have fulfilled our other ethical responsibilities in accordance with these requirements. Based on our audits and the reports of other auditors, we believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

## **Key audit matters**

Key audit matters are those matters that, in our professional judgment, were of most significance in our audit of the Company's 2023 parent company only financial statements. These matters were addressed in the context of our audit of the parent company only financial statements as a whole and, in forming our opinion thereon, we do not provide a separate opinion on these matters.

Key audit matters of the Company's 2023 parent company only financial statements are as follows:

### **Valuation of inventories**

#### Description

Refer to Note 4(10) for accounting policies on the valuation of inventories, Note 5(2) for the uncertainty of significant accounting estimations and assumptions relating to valuation of inventories, and Note 6(6) for the details of allowance for inventory valuation loss. As of December 31, 2023, the carrying amount of inventories and allowance for inventory valuation loss are \$720,543 thousand and \$16,389 thousand, respectively.

The Company is primarily engaged in the manufacture and sales of human medicine. Due to the influence of market demand and short expiration date of medicines, there is a risk of market price decline and obsolescence of inventories. The Company measures inventories at the lower of cost and net realisable value. The net realisable values of obsolete inventories are determined based on the historical information on the selling price. Given that the valuation of inventories is subject to uncertainty of assumptions and the accounting estimations will have significant influence on the inventory values, we considered the valuation of inventories a key audit matter.

#### How our audit addressed the matter

We performed the following key audit procedures on the above key audit matter:

1. Assessed the reasonableness of policies on allowance for inventory valuation loss.

2. Assessed the effectiveness of the management's inventory control, based on our understanding of the operations of the warehouse management, inspected the annual inventory taking plan and performed our observation.
3. Tested whether the basis of inventory aging used in calculating the net realisable value of inventory is consistent with the Company's policy.
4. Validated the net realisable value of inventories and the adequacy of allowance for inventory valuation loss.

### **Existence of domestic sales revenue from human medicines**

#### Description

Refer to Note 4(27) for accounting policies on revenue recognition. Revenue is recognised when control of the products has transferred, being when the products are delivered to the customer, the customer has full discretion over the channel and price to sell the products, and there is no unfulfilled obligation that could affect the customer's acceptance of the products.

The Company is primarily engaged in the manufacturing and sales of human medicines. The Company's sales is mainly domestic-based and its customers are numerous, including hospitals, clinics and pharmacies all over the country. Since the sales transactions are numerous and would require a longer period for verification, we considered the existence of domestic sales revenue from human medicines a key audit matter.

#### How our audit addressed the matter

We performed the following key audit procedures for the above matter:

1. Assessed the consistency and effectiveness of internal control relevant to sales revenue recognition.
2. Assessed basic information of the major customers, including the details of the chairman and major shareholders, registered address, principal place of business, capital and main business activities, etc.
3. Selected samples of sales transactions and checked against related supporting documentation, including unit prices, quantities, reasonableness of sales allowance

recognition, waybill and subsequent cash collection.

### **Other matter – Reference to the audits of other auditors**

We did not audit the financial statements of an investment accounted for under equity method which were audited by other auditors. Therefore, our opinion expressed herein, insofar as it relates to the amounts included in respect of this associate, is based solely on the reports of the other auditors. The balance of this investment accounted for under equity method amounted to \$243,423 thousand and \$235,502 thousand, constituting 3.64% and 3.62% of total assets as of December 31, 2023 and 2022, respectively, and the comprehensive income recognised from subsidiaries, associates and joint ventures accounted for under equity method amounted to \$4,679 thousand and \$33,360 thousand, constituting 0.47% and 3.96% of total comprehensive income for the years then ended, respectively.

### **Responsibilities of management and those charged with governance for the parent company only financial statements**

Management is responsible for the preparation and fair presentation of the parent company only financial statements in accordance with the Regulations Governing the Preparation of Financial Reports by Securities Issuers, and for such internal control as management determines is necessary to enable the preparation of parent company only financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the parent company only financial statements, management is responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

Those charged with governance, including audit committee, are responsible for overseeing

the Company's financial reporting process.

### **Auditors' responsibilities for the audit of the parent company only financial statements**

Our objectives are to obtain reasonable assurance about whether the parent company only financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditors' report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with the Standards on Auditing of the Republic of China will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these parent company only financial statements.

As part of an audit in accordance with the Standards on Auditing of the Republic of China, we exercise professional judgment and professional skepticism throughout the audit. We also:

1. Identify and assess the risks of material misstatement of the parent company only financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
2. Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control.
3. Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.

4. Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditors' report to the related disclosures in the parent company only financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditors' report. However, future events or conditions may cause the Company to cease to continue as a going concern.
5. Evaluate the overall presentation, structure and content of the parent company only financial statements, including the disclosures, and whether the parent company only financial statements represent the underlying transactions and events in a manner that achieves fair presentation.
6. Obtain sufficient appropriate audit evidence regarding the financial information of the entities or business activities within the Company to express an opinion on the parent company only financial statements. We are responsible for the direction, supervision and performance of the audit. We remain solely responsible for our audit opinion.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

From the matters communicated with those charged with governance, we determine those matters that were of most significance in the audit of the parent company only financial statements of the current period and are therefore the key audit matters. We describe these matters in our auditors' report unless law or regulation precludes public disclosure about the matter or when, in extremely rare circumstances, we determine that a matter should not be communicated in our report because the adverse consequences of doing so would reasonably be expected to outweigh the public interest benefits of such communication.

Tien, Chung-Yu

Independent Accountants

Yeh, Fang-Ting

PricewaterhouseCoopers, Taiwan

Republic of China

February 27, 2024

-----  
The accompanying parent company only financial statements are not intended to present the financial position and results of operations and cash flows in accordance with accounting principles generally accepted in countries and jurisdictions other than the Republic of China. The standards, procedures and practices in the Republic of China governing the audit of such financial statements may differ from those generally accepted in countries and jurisdictions other than the Republic of China. Accordingly, the accompanying parent company only financial statements and independent auditors' report are not intended for use by those who are not informed about the accounting principles or auditing standards generally accepted in the Republic of China, and their applications in practice.

As the financial statements are the responsibility of the management, PricewaterhouseCoopers cannot accept any liability for the use of, or reliance on, the English translation or for any errors or misunderstandings that may derive from the translation.



STANDARD CHEM. & PHARM. CO., LTD.  
PARENT COMPANY ONLY BALANCE SHEETS  
(EXPRESSED IN THOUSANDS OF NEW TAIWAN DOLLARS)

Assets		Notes	December 31, 2023		December 31, 2022			
			AMOUNT	%	AMOUNT	%		
Current assets								
1100	Cash and cash equivalents	6(1)	\$	715,774	11	\$	858,252	13
1136	Financial assets at amortised cost - current	6(1)		8,000	-		-	-
1150	Notes receivable, net	6(4), 7 and 12		109,055	2		100,411	2
1170	Accounts receivable, net	6(4), 7 and 12		578,405	9		533,695	8
1200	Other receivables	6(5) and 7		11,314	-		72,290	1
130X	Inventories	5(2) and 6(6)		704,154	10		562,398	9
1410	Prepayments			48,900	1		47,159	1
1479	Other current assets			4,231	-		24,973	-
11XX	Total current assets			2,179,833	33		2,199,178	34
Non-current assets								
1510	Financial assets at fair value through profit or loss - non-current	5(2) and 6(2)		11,604	-		10,561	-
1517	Financial assets at fair value through other comprehensive income - non-current	5(2) and 6(3)		343,837	5		248,366	4
1550	Investments accounted for under equity method	6(7)(27) and 7		2,930,322	44		2,820,888	43
1600	Property, plant and equipment	6(7)(8) and 7		994,618	15		1,003,055	16
1755	Right-of-use assets	6(9) and 7		12,976	-		15,711	-
1760	Investment property, net	6(8)(10)		62,773	1		62,987	1
1780	Intangible assets	6(11)		4,160	-		6,374	-
1840	Deferred income tax assets	6(25)		82,778	1		79,609	1
1915	Prepayments for equipment	6(8)		12,012	-		27,128	1
1920	Guarantee deposits paid			38,291	1		25,685	-
1990	Other non-current assets			6,619	-		5,519	-
15XX	Total non-current assets			4,499,990	67		4,305,883	66
1XXX	TOTAL ASSETS		\$	6,679,823	100	\$	6,505,061	100

(Continued)

STANDARD CHEM. & PHARM. CO., LTD.  
PARENT COMPANY ONLY BALANCE SHEETS  
(EXPRESSED IN THOUSANDS OF NEW TAIWAN DOLLARS)

Liabilities and Equity			December 31, 2023		December 31, 2022	
Notes			AMOUNT	%	AMOUNT	%
Current liabilities						
2100	Short-term borrowings	6(12)	\$ 460,000	7	\$ 870,000	14
2130	Contract liabilities - current	6(18)	34,899	1	35,430	1
2150	Notes payable		134,316	2	141,490	2
2170	Accounts payable	7	166,760	2	142,739	2
2200	Other payables		252,697	4	248,593	4
2230	Current income tax liabilities	6(25)	108,521	2	83,846	1
2280	Lease liabilities - current	6(9) and 7	5,290	-	4,444	-
2310	Receipts in advance		619	-	942	-
21XX	Total current liabilities		1,163,102	18	1,527,484	24
Non-current liabilities						
2570	Deferred income tax liabilities	6(25)	61,992	1	64,893	1
2580	Lease liabilities - non-current	6(9) and 7	7,923	-	11,540	-
2640	Net defined benefit liability - non-current	6(13)	139,057	2	147,770	2
2645	Guarantee deposits received		8,733	-	200	-
25XX	Total non-current liabilities		217,705	3	224,403	3
2XXX	Total liabilities		1,380,807	21	1,751,887	27
Equity						
Share capital						
3110	Common stock	6(14)	1,786,961	27	1,786,961	28
3200	Capital surplus	6(7)(15)(27)	223,886	3	220,484	3
	Retained earnings	6(3)(7)(16)(17)				
3310	Legal reserve		878,245	13	793,498	12
3320	Special reserve		115,935	2	110,329	2
3350	Unappropriated retained earnings		2,280,812	34	1,957,837	30
3400	Other equity interest	6(3)(7)(17)	13,177	-	( 115,935)	( 2)
3XXX	Total equity		5,299,016	79	4,753,174	73
	Significant contingent liabilities and unrecognised contract commitments	9				
3X2X	TOTAL LIABILITIES AND EQUITY		\$ 6,679,823	100	\$ 6,505,061	100

The accompanying notes are an integral part of these parent company only financial statements.

STANDARD CHEM. & PHARM. CO., LTD.  
PARENT COMPANY ONLY STATEMENTS OF COMPREHENSIVE INCOME  
(EXPRESSED IN THOUSANDS OF NEW TAIWAN DOLLARS, EXCEPT EARNINGS PER SHARE DATA)

				For the years ended December 31,			
				2023		2022	
Items	Notes			AMOUNT	%	AMOUNT	%
4000 Operating revenue	6(18) and 7		\$	2,989,635	100	\$	2,772,204
5000 Operating costs	6(6)(9)(11)(13)(23)(24) and 7	(		1,497,249	50	(	1,453,091
5900 Net operating margin				1,492,386	50		1,319,113
Operating expenses	6(9)(11)(13)(23)(24) and 7						47
6100 Selling expenses		(		458,440	16	(	417,752
6200 General and administrative expenses		(		186,240	6	(	166,223
6300 Research and development expenses		(		189,105	6	(	148,410
6450 Expected credit (loss) gain	12	(		281	-		837
6000 Total operating expenses		(		834,066	28	(	731,548
6900 Operating profit				658,320	22		587,565
Non-operating income and expenses							21
7100 Interest income	6(19)			31,593	1		11,232
7010 Other income	6(3)(5)(10)(20) and 7			105,492	3		56,220
7020 Other gains and losses	6(2)(9)(21), 7 and 12			7,613	-		75,984
7050 Finance costs	6(8)(9)(22) and 7	(		10,900	-	(	7,821
7070 Share of profit of subsidiaries, associates and joint ventures accounted for under equity method	6(7)						
7000 Total non-operating income and expenses				202,268	7		205,039
7900 Profit before income tax				336,066	11		340,654
7950 Income tax expense	6(25)	(		159,500	5	(	112,811
8200 Profit for the year			\$	834,886	28	\$	815,408
<b>Other comprehensive income (loss)</b>							
<b>Components of other comprehensive income (loss) that will not be reclassified to profit or loss</b>							
8311 Remeasurement of defined benefit plans	6(13)		\$	2,895	-	\$	27,915
8316 Unrealised gains (losses) from investments in equity instruments measured at fair value through other comprehensive income	6(3)(17)			152,452	5	(	14,235
8330 Share of other comprehensive income of associates and joint ventures accounted for under equity method	6(7)(17)			495	-		3,870
8349 Income tax related to components of other comprehensive loss	6(25)	(		578	-	(	5,583
<b>Components of other comprehensive income (loss) that will be reclassified to profit or loss</b>							
8361 Financial statements translation differences of foreign operations	6(7)(17)	(		970	-		14,492
8300 Total other comprehensive income for the year			\$	154,294	5	\$	26,459
8500 Total comprehensive income for the year			\$	989,180	33	\$	841,867
Earnings per share (in dollars)	6(26)						
9750 Basic			\$		4.67	\$	4.56
9850 Diluted			\$		4.67	\$	4.56

The accompanying notes are an integral part of these parent company only financial statements.

STANDARD CHEM. & PHARM. CO., LTD.  
PARENT COMPANY ONLY STATEMENTS OF CHANGES IN EQUITY  
(EXPRESSED IN THOUSANDS OF NEW TAIWAN DOLLARS)

		Capital Surplus					Retained Earnings			Other Equity Interest		
	Notes	Common stock	Additional paid-in capital	Difference between the price for acquisition or disposal of subsidiaries and carrying amount	Change in net equity of associates and joint ventures accounted for using the equity method	Others	Legal reserve	Special reserve	Unappropriated retained earnings	Financial statements translation differences of foreign operations	Unrealised gains or losses from financial assets measured at fair value through other comprehensive income	Total equity
<u>For the year ended December 31, 2022</u>												
Balance at January 1, 2022		\$ 1,786,961	\$ 143,353	\$ 57,377	\$ 3,341	\$ 242	\$ 709,879	\$ -	\$ 1,751,052	(\$ 20,974 )	(\$ 89,355 )	\$ 4,341,876
Profit for the year		-	-	-	-	-	-	-	815,408	-	-	815,408
Other comprehensive income (loss) for the year	6(17)	-	-	-	-	-	-	-	26,107	14,492	( 14,140 )	26,459
Total comprehensive income (loss) for the year		-	-	-	-	-	-	-	841,515	14,492	( 14,140 )	841,867
Difference between proceeds from acquisition or disposal of subsidiaries and book value	6(7)	-	-	3,521	-	-	-	-	-	-	-	3,521
Adjustment to capital surplus due to associates' adjustment of capital surplus	6(7)(15)	-	-	-	3,744	-	-	-	-	-	-	3,744
Overdue cash dividends payable	6(15)	-	-	-	-	171	-	-	-	-	-	171
Disposal of financial assets at fair value through other comprehensive income	6(3)(17)	-	-	-	-	-	-	-	5,958	-	( 5,958 )	-
Appropriations of 2021 earnings:												
Legal reserve		-	-	-	-	-	83,619	-	( 83,619 )	-	-	-
Special reserve		-	-	-	-	-	-	110,329	( 110,329 )	-	-	-
Cash dividends	6(16)	-	-	-	-	-	-	-	( 446,740 )	-	-	( 446,740 )
Effect of organisational restructuring	6(7)(15)	-	8,735	-	-	-	-	-	-	-	-	8,735
Balance at December 31, 2022		\$ 1,786,961	\$ 152,088	\$ 60,898	\$ 7,085	\$ 413	\$ 793,498	\$ 110,329	\$ 1,957,837	(\$ 6,482 )	(\$ 109,453 )	\$ 4,753,174
<u>For the year ended December 31, 2023</u>												
Balance at January 1, 2023		\$ 1,786,961	\$ 152,088	\$ 60,898	\$ 7,085	\$ 413	\$ 793,498	\$ 110,329	\$ 1,957,837	(\$ 6,482 )	(\$ 109,453 )	\$ 4,753,174
Profit for the year		-	-	-	-	-	-	-	834,886	-	-	834,886
Other comprehensive income (loss) for the year	6(17)	-	-	-	-	-	-	-	2,717	( 970 )	152,547	154,294
Total comprehensive income (loss) for the year		-	-	-	-	-	-	-	837,603	( 970 )	152,547	989,180
Adjustment to capital surplus due to associates' adjustment of capital surplus	6(7)(15)	-	-	-	3,281	-	-	-	-	-	-	3,281
Overdue cash dividends payable	6(15)	-	-	-	-	121	-	-	-	-	-	121
Disposal of financial assets at fair value through other comprehensive income	6(3)(17)	-	-	-	-	-	-	-	22,465	-	( 22,465 )	-
Appropriations of 2022 earnings:												
Legal reserve		-	-	-	-	-	84,747	-	( 84,747 )	-	-	-
Special reserve		-	-	-	-	-	-	5,606	( 5,606 )	-	-	-
Cash dividends	6(16)	-	-	-	-	-	-	-	( 446,740 )	-	-	( 446,740 )
Balance at December 31, 2023		\$ 1,786,961	\$ 152,088	\$ 60,898	\$ 10,366	\$ 534	\$ 878,245	\$ 115,935	\$ 2,280,812	(\$ 7,452 )	\$ 20,629	\$ 5,299,016

The accompanying notes are an integral part of these parent company only financial statements.

STANDARD CHEM. & PHARM. CO., LTD.  
PARENT COMPANY ONLY STATEMENTS OF CASH FLOWS  
(EXPRESSED IN THOUSANDS OF NEW TAIWAN DOLLARS)

		For the years ended December 31,	
	Notes	2023	2022
<b>CASH FLOWS FROM OPERATING ACTIVITIES</b>			
Profit before tax		\$ 994,386	\$ 928,219
Adjustments			
Adjustments to reconcile profit (loss)			
Net gain on financial assets at fair value through profit and loss	6(2)(21)	( 1,043 )	( 712 )
Expected credit losses (gains)	12	281	( 837 )
Provision (reversal of allowance) for inventory market price decline	6(6)	3,760	( 3,807 )
Share of profit of subsidiaries, associates and joint ventures accounted for under equity method	6(7)	( 202,268 )	( 205,039 )
Property, plant and equipment transferred to expense	6(8)(28)	2,134	-
Depreciation	6(8)(9)(10)	102,116	95,641
Net loss on disposal of property, plant and equipment	6(21)	-	1,113
Gain from lease modification	6(9)(21)	-	( 8 )
Amortisation	6(23)	7,815	9,605
Dividend income	6(3)(20)	( 10,034 )	( 9,604 )
Interest income	6(19)	( 31,593 )	( 11,232 )
Interest expenses	6(22)	10,900	7,821
Changes in operating assets and liabilities			
Changes in operating assets			
Notes receivable		( 8,644 )	843
Accounts receivable		( 44,991 )	( 12,823 )
Other receivables		61,032	83,216
Inventories		( 145,516 )	( 58,097 )
Prepayments		( 7,319 )	( 10,577 )
Other current assets		20,742	( 24,177 )
Changes in operating liabilities			
Contract liabilities - current		( 531 )	( 5,139 )
Notes payable		( 3,650 )	39,333
Accounts payable		24,021	( 22,229 )
Other payables		15,061	( 10,040 )
Receipts in advance		( 323 )	( 448 )
Net defined benefit liability - non-current		( 5,818 )	( 20,649 )
Cash inflow generated from operations		780,518	770,373
Dividends received		111,317	83,670
Interest received		31,537	8,832
Interest paid		( 11,077 )	( 7,540 )
Income tax paid		( 141,473 )	( 95,977 )
Net cash flows from operating activities		770,822	759,358

(Continued)

STANDARD CHEM. & PHARM. CO., LTD.  
PARENT COMPANY ONLY STATEMENTS OF CASH FLOWS  
(EXPRESSED IN THOUSANDS OF NEW TAIWAN DOLLARS)

		For the years ended December 31,	
	Notes	2023	2022
<b>CASH FLOWS FROM INVESTING ACTIVITIES</b>			
Increase in financial assets at amortised cost - current		( \$ 8,000 )	\$ -
Acquisition of financial assets at fair value through other comprehensive income - non-current		( 18,983 )	( 60,632 )
Proceeds from disposal of financial assets at fair value through other comprehensive income - non-current	6(3)	75,964	23,305
Acquisition of investments accounted for under equity method	6(28)	-	( 51,563 )
Proceeds from disposal of investments accounted for under equity method	6(7)	-	9,156
Cash paid for acquisition of property, plant and equipment	6(28)	( 69,060 )	( 159,723 )
Interest paid for acquisition of property, plant and equipment	6(8)(22)(28)	( 374 )	( 638 )
Proceeds from disposal of property, plant and equipment		-	722
Acquisition of intangible assets	6(11)	( 817 )	( 3,564 )
Increase in prepayment for equipment		( 19,999 )	( 88,852 )
(Increase) decrease in guarantee deposits paid		( 12,606 )	11,947
Proceeds from disposals of other non-current assets	6(28)	-	38,364
Increase in other non-current assets		( 5,884 )	( 4,530 )
Cash received from segment spin-off	6(7)	-	6,973
Net cash flows used in investing activities		( 59,759 )	( 279,035 )
<b>CASH FLOWS FROM FINANCING ACTIVITIES</b>			
Increase in short-term borrowings	6(29)	460,000	497,500
Decrease in short-term borrowings	6(29)	( 870,000 )	( 338,000 )
Payments of lease liabilities	6(29)	( 5,390 )	( 4,842 )
Increase (decrease) in guarantee deposit received	6(29)	8,533	( 35 )
Overdue cash dividends payable	6(15)	56	171
Payment of cash dividends	6(16)	( 446,740 )	( 446,740 )
Net cash flows used in financing activities		( 853,541 )	( 291,946 )
Net (decrease) increase in cash and cash equivalents		( 142,478 )	188,377
Cash and cash equivalents at beginning of year	6(1)	858,252	669,875
Cash and cash equivalents at end of year	6(1)	\$ 715,774	\$ 858,252

The accompanying notes are an integral part of these parent company only financial statements.

STANDARD CHEM. & PHARM. CO., LTD.  
NOTES TO THE PARENT COMPANY ONLY FINANCIAL STATEMENTS  
FOR THE YEARS ENDED DECEMBER 31, 2023 AND 2022  
(EXPRESSED IN THOUSANDS OF NEW TAIWAN DOLLARS,  
EXCEPT AS OTHERWISE INDICATED)

1. HISTORY AND ORGANISATION

(1) Standard Chem. & Pharm. Co., Ltd. (the ‘Company’) was incorporated on June 30, 1967 under the provisions of the Company Act of the Republic of China (R.O.C.) and other regulations. The Company is primarily engaged in the manufacturing and sales of Chinese and western medicine, cosmetics, beverage, normal instruments and medical instruments.

(2) The Company has been listed on the Taiwan Stock Exchange starting from December 1995.

2. THE DATE OF AUTHORISATION FOR ISSUANCE OF THE PARENT COMPANY ONLY FINANCIAL STATEMENTS AND PROCEDURES FOR AUTHORISATION

These parent company only financial statements were authorised for issuance by the Board of Directors on February 27, 2024.

3. APPLICATION OF NEW STANDARDS, AMENDMENTS AND INTERPRETATIONS

(1) Effect of the adoption of new issuances of or amendments to International Financial Reporting Standards (“IFRS<sup>®</sup>”) Accounting Standards that came into effect as endorsed by the Financial Supervisory Commission (“FSC”)

New standards, interpretations and amendments endorsed by the FSC and became effective from 2023 are as follows:

New Standards, Interpretations and Amendments	Effective date by International Accounting Standards Board (“IASB”)
Amendments to IAS 1, ‘Disclosure of accounting policies’	January 1, 2023
Amendments to IAS 8, ‘Definition of accounting estimates’	January 1, 2023
Amendments to IAS 12, ‘Deferred tax related to assets and liabilities arising from a single transaction’	January 1, 2023
Amendments to IAS 12, ‘International tax reform - pillar two model rules’	May 23, 2023
The above standards and interpretations have no significant impact to the Company’s financial condition and financial performance based on the Company’s assessment.	

(2) Effect of new issuances of or amendments to IFRS Accounting Standards as endorsed by the FSC but not yet adopted by the Company

New standards, interpretations and amendments endorsed by the FSC and will become effective from 2024 are as follows:

New Standards, Interpretations and Amendments	Effective date by IASB
Amendments to IFRS 16, 'Lease liability in a sale and leaseback'	January 1, 2024
Amendments to IAS 1, 'Classification of liabilities as current or non-current'	January 1, 2024
Amendments to IAS 1, 'Non-current liabilities with covenants'	January 1, 2024
Amendments to IAS 7 and IFRS 7, 'Supplier finance arrangements'	January 1, 2024

The above standards and interpretations have no significant impact to the Company's financial condition and financial performance based on the Company's assessment.

(3) IFRS Accounting Standards issued by IASB but not yet endorsed by the FSC

New standards, interpretations and amendments issued by IASB but not yet included in the IFRSs as endorsed by the FSC are as follows:

New Standards, Interpretations and Amendments	Effective date by IASB
Amendments to IFRS 10 and IAS 28, 'Sale or contribution of assets between an investor and its associate or joint venture'	To be determined by IASB
IFRS 17, 'Insurance contracts'	January 1, 2023
Amendments to IFRS 17, 'Insurance contracts'	January 1, 2023
Amendment to IFRS 17, 'Initial application of IFRS 17 and IFRS 9 – comparative information'	January 1, 2023
Amendments to IAS 21, 'Lack of exchangeability'	January 1, 2025

The above standards and interpretations have no significant impact to the Company's financial condition and financial performance based on the Company's assessment.

4. SUMMARY OF MATERIAL ACCOUNTING POLICIES

The principal accounting policies applied in the preparation of these parent company only financial statements are set out below. These policies have been consistently applied to all the periods presented, unless otherwise stated.

(1) Compliance statement

The parent company only financial statements of the Company have been prepared in accordance with the Regulations Governing the Preparation of Financial Reports by Securities Issuers.

(2) Basis of preparation

A. Except for the following items, the parent company only financial statements have been prepared under the historical cost convention:

- (a) Financial assets at fair value through profit or loss.
- (b) Financial assets at fair value through other comprehensive income.



(c) Defined benefit liabilities recognised based on the net amount of pension fund assets less present value of defined benefit obligation.

B. The preparation of financial statements in conformity with International Financial Reporting Standards, International Accounting Standards, IFRIC<sup>®</sup> Interpretations, and SIC<sup>®</sup> Interpretations that came into effect as endorsed by the FSC (collectively referred herein as the “IFRSs” ) requires the use of certain critical accounting estimates. It also requires management to exercise its judgement in the process of applying the Company’s accounting policies. The areas involving a higher degree of judgement or complexity, or areas where assumptions and estimates are significant to the parent company only financial statements are disclosed in Note 5, ‘CRITICAL ACCOUNTING JUDGEMENTS, ESTIMATES AND KEY SOURCES OF ASSUMPTION UNCERTAINTY’.

(3) Foreign currency translation

Items included in the financial statements are measured using the currency of the primary economic environment in which the entity operates (the “functional currency”). The parent company only financial statements are presented in New Taiwan dollars, which is the Company’s functional and presentation currency.

A. Foreign currency transactions are translated into the functional currency using the exchange rates prevailing at the dates of the transactions or valuation where items are remeasured. Foreign exchange gains and losses resulting from the settlement of such transactions are recognised in profit or loss in the period in which they arise.

B. Monetary assets and liabilities denominated in foreign currencies at the period end are re-translated at the exchange rates prevailing at the balance sheet date. Exchange differences arising upon re-translation at the balance sheet date are recognised in profit or loss.

C. Non-monetary assets and liabilities denominated in foreign currencies held at fair value through profit or loss are re-translated at the exchange rates prevailing at the balance sheet date; their translation differences are recognised in profit or loss. Non-monetary assets and liabilities denominated in foreign currencies held at fair value through other comprehensive income are re-translated at the exchange rates prevailing at the balance sheet date; their translation differences are recognised in other comprehensive income. However, non-monetary assets and liabilities denominated in foreign currencies that are not measured at fair value are translated using the historical exchange rates at the dates of the initial transactions.

D. All other foreign exchange gains and losses based on the nature of those transactions are presented in the statement of comprehensive income within other gains and losses.

(4) Classification of current and non-current items

A. Assets that meet one of the following criteria are classified as current assets; otherwise they are classified as non-current assets:

(a) Assets arising from operating activities that are expected to be realised, or are intended to be sold or consumed within the normal operating cycle;

- (b) Assets held mainly for trading purposes;
  - (c) Assets that are expected to be realised within 12 months from the balance sheet date;
  - (d) Cash and cash equivalents, excluding restricted cash and cash equivalents and those that are to be exchanged or used to settle liabilities more than twelve months after the balance sheet date.
- B. Liabilities that meet one of the following criteria are classified as current liabilities; otherwise they are classified as non-current liabilities:
- (a) Liabilities that are expected to be settled within the normal operating cycle;
  - (b) Liabilities arising mainly from trading activities;
  - (c) Liabilities that are to be settled within 12 months from the balance sheet date;
  - (d) Liabilities for which the repayment date cannot be extended unconditionally to more than twelve months after the balance sheet date. Terms of a liability that could, at the option of the counterparty, result in its settlement by the issue of equity instruments do not affect its classification.

(5) Cash equivalents

- A. Cash equivalents refer to short-term, highly liquid investments that are readily convertible to known amounts of cash and which are subject to an insignificant risk of changes in value.
- B. Time deposits and repurchase bonds that meet the definition above and are held for the purpose of meeting short-term cash commitments in operations are classified as cash equivalents.

(6) Financial assets at fair value through profit or loss

- A. Financial assets at fair value through profit or loss are financial assets that are not measured at amortised cost or fair value through other comprehensive income.
- B. On a regular way purchase or sale basis, financial assets at fair value through profit or loss are recognised and derecognised using trade date accounting.
- C. At initial recognition, the Company measures the financial assets at fair value and recognises the transaction costs in profit or loss. The Company subsequently measures the financial assets at fair value, and recognises the gain or loss in profit or loss.
- D. The Company recognises the dividend income when the right to receive payment is established, future economic benefits associated with the dividend will flow to the Company and the amount of the dividend can be measured reliably.

(7) Financial assets at amortised cost

- A. Financial assets at a mortised cost are those that meet all of the following criteria:
  - (a) The objective of the Company's business model is achieved by collecting contractual cash flows.
  - (b) The assets' contractual cash flows represent solely payments of principal and interest.
- B. The Company's time deposits which do not fall under cash equivalents are those with a short maturity period and are measured at initial investment amount as the effect of discounting is immaterial.

(8) Financial assets at fair value through other comprehensive income

- A. Financial assets at fair value through other comprehensive income comprise equity securities which are not held for trading, and for which the Company has made an irrevocable election at initial recognition to recognise changes in fair value in other comprehensive income.
- B. On a regular way purchase or sale basis, financial assets at fair value through other comprehensive income are recognised and derecognised using trade date accounting.
- C. At initial recognition, the Company measures the financial assets at fair value plus transaction costs. The Company subsequently measures the financial assets at fair value:  
The changes in fair value of equity investments that were recognised in other comprehensive income are reclassified to retained earnings and are not reclassified to profit or loss following the derecognition of the investment. Dividends are recognised as revenue when the right to receive payment is established, future economic benefits associated with the dividend will flow to the Company and the amount of the dividend can be measured reliably.

(9) Accounts and notes receivable

- A. Accounts and notes receivable entitle the Company a legal right to receive consideration in exchange for transferred goods or rendered services.
- B. The short-term accounts and notes receivable without bearing interest are subsequently measured at initial invoice amount as the effect of discounting is immaterial.

(10) Inventories

Inventories are stated at the lower of cost and net realisable value. Cost is determined using the weighted-average method. The cost of finished goods and work in process comprises raw materials, direct labour, other direct costs and related production overheads (allocated based on normal operating capacity). It excludes borrowing costs. The item by item approach is used in applying the lower of cost and net realisable value. Net realisable value is the estimated selling price in the ordinary course of business, less the estimated costs of completion and the estimated costs necessary to make the sale. If the cost exceeds net realisable value, valuation loss is accrued and recognised in operating costs. If the net realisable value reverses, valuation is eliminated within credit balance and is recognised as deduction of operating costs.

(11) Impairment of financial assets

For financial assets at amortised cost, at each reporting date, the Company recognises the impairment provision for 12 months expected credit losses if there has not been a significant increase in credit risk since initial recognition or recognises the impairment provision for the lifetime expected credit losses (ECLs) if such credit risk has increased since initial recognition after taking into consideration all reasonable and verifiable information that includes forecasts. On the other hand, for accounts receivable that do not contain a significant financing component, the Company recognises the impairment provision for lifetime ECLs.

(12) Derecognition of financial assets

The Company derecognises a financial asset when the contractual rights to receive the cash flows from the financial asset expire.

(13) Leasing arrangements (lessor) — operating leases

Lease income from an operating lease (net of any incentives given to the lessee) is recognised in profit or loss on a straight-line basis over the lease term.

(14) Investments accounted for under equity method / subsidiaries and associates

- A. Subsidiaries are all entities controlled by the Company. The Company controls an entity when the Company is exposed, or has rights, to variable returns from its involvement with the entity and has the ability to affect those returns through its power over the entity.
- B. Unrealised gains or losses occurred on the transactions between the Company and subsidiaries have been eliminated. The accounting policies of the subsidiaries have been adjusted where necessary to ensure consistency with the policies adopted by the Company.
- C. The Company's share of its subsidiaries' post-acquisition profits or losses is recognised in profit or loss, and its share of post-acquisition movements in other comprehensive income is recognised in other comprehensive income. When the Company's share of losses in a subsidiary equals or exceeds its interest in the subsidiary, the Company continues to recognise losses proportionate to its ownership.
- D. If changes in the Company's shares in subsidiaries do not result in loss in control (transactions with non-controlling interest), transactions shall be considered as equity transactions, which are transactions between owners. Difference of adjustment of non-controlling interest and fair value of consideration paid or received is recognised in equity.
- E. Associates are all entities over which the Company has significant influence but not control. In general, it is presumed that the investor has significant influence, if an investor holds, directly or indirectly 20 percent or more of the voting power of the investee. Investments in associates are accounted for under the equity method and are initially recognised at cost.
- F. The Company's share of its associates' post-acquisition profits or losses is recognised in profit or loss, and its share of post-acquisition movements in other comprehensive income is recognised in other comprehensive income. When the Company's share of losses in an associate equals or exceeds its interest in the associate, including any other unsecured receivables, the Company does not recognise further losses, unless it has incurred legal or constructive obligations or made payments on behalf of the associate.
- G. When changes in an associate's equity do not arise from profit or loss or other comprehensive income of the associate and such changes do not affect the Company's ownership percentage of the associate, the Company recognises the Company's share of change in equity of the associate in 'capital surplus' in proportion to its ownership.
- H. Unrealised gains on transactions between the Company and its associates are eliminated to the extent of the Company's interest in the associates. Unrealised losses are also eliminated unless

the transaction provides evidence of an impairment of the asset transferred. Accounting policies of associates have been adjusted where necessary to ensure consistency with the policies adopted by the Company.

- I. In the case that an associate issues new shares and the Company does not subscribe or acquire new shares proportionately, which results in a change in the Company's ownership percentage of the associate but maintains significant influence on the associate, then 'capital surplus' and 'investments accounted for under equity method' shall be adjusted for the increase or decrease of its share of equity interest. If the above condition causes a decrease in the Company's ownership percentage of the associate, in addition to the above adjustment, the amounts previously recognised in other comprehensive income in relation to the associate are reclassified to profit or loss proportionately on the same basis as would be required if the relevant assets or liabilities were disposed of.
- J. When the Company disposes its investment in an associate and loses significant influence over this associate, the amounts previously recognised in other comprehensive income in relation to the associate, are reclassified to profit or loss, on the same basis as would be required if the relevant assets or liabilities were disposed of. If it retains significant influence over this associate, the amounts previously recognised in other comprehensive income in relation to the associate are reclassified to profit or loss proportionately in accordance with the aforementioned approach.
- K. When the Company disposes its investment in an associate and loses significant influence over this associate, the amounts previously recognised as capital surplus in relation to the associate are transferred to profit or loss. If it retains significant influence over this associate, the amounts previously recognised as capital surplus in relation to the associate are transferred to profit or loss proportionately.
- L. Pursuant to the Regulations Governing the Preparation of Financial Reports by Securities Issuers, profit (loss) of the current period and other comprehensive income in the parent company only financial statements shall equal to the amount attributable to owners of the parent in the financial statements prepared with basis for consolidation. Owners' equity in the parent company only financial statements shall equal to equity attributable to owners of the parent in the financial statements prepared with basis for consolidation.

(15) Property, plant and equipment

- A. Property, plant and equipment are initially recorded at cost. Borrowing costs incurred during the construction period are capitalised.
- B. Subsequent costs are included in the asset's carrying amount or recognised as a separate asset, as appropriate, only when it is probable that future economic benefits associated with the item will flow to the Company and the cost of the item can be measured reliably. The carrying amount of the replaced part is derecognised. All other repairs and maintenance are charged to profit or loss during the financial period in which they are incurred.
- C. Land is not depreciated. Other property, plant and equipment apply cost model and are

depreciated using the straight-line method to allocate their cost over their estimated useful lives. Each part of an item of property, plant, and equipment with a cost that is significant in relation to the total cost of the item must be depreciated separately.

- D. The assets' residual values, useful lives and depreciation methods are reviewed, and adjusted if appropriate, at each financial year-end. If expectations for the assets' residual values and useful lives differ from previous estimates or the patterns of consumption of the assets' future economic benefits embodied in the assets have changed significantly, any change is accounted for as a change in estimate under IAS 8, 'Accounting Policies, Changes in Accounting Estimates and Errors', from the date of the change. The estimated useful lives of property, plant and equipment are as follows:

Assets	Useful Life
Buildings (including auxiliary equipment)	2 ~ 60 years
Machinery and equipment	2 ~ 15 years
Utility equipment	3 ~ 20 years
Transportation equipment	2 ~ 15 years
Office equipment	2 ~ 9 years
Other equipment	2 ~ 15 years

(16) Leasing arrangements (lessee) — right-of-use assets / lease liabilities

- A. Leases are recognised as a right-of-use asset and a corresponding lease liability at the date at which the leased asset is available for use by the Company. For short-term leases or leases of low-value assets, lease payments are recognised as an expense on a straight-line basis over the lease term.
- B. Lease liabilities include the net present value of the remaining lease payments at the commencement date, discounted using the incremental borrowing interest rate. Lease payments are comprised of fixed payments, less any lease incentives receivable. The Company subsequently measures the lease liability at amortised cost using the interest method and recognises interest expense over the lease term. The lease liability is remeasured and the amount of remeasurement is recognised as an adjustment to the right-of-use asset when there are changes in the lease term or lease payments and such changes do not arise from contract modifications.
- C. At the commencement date, the right-of-use asset is stated at cost comprising the following:
- The amount of the initial measurement of lease liability; and
  - Any lease payments made at or before the commencement date.

The right-of-use asset is measured subsequently using the cost model and is depreciated from the commencement date to the earlier of the end of the asset's useful life or the end of the lease term. When the lease liability is remeasured, the amount of remeasurement is recognised as an adjustment to the right-of-use asset.

- D. For lease modifications that decrease the scope of the lease, the lessee shall decrease the carrying amount of the right-of-use asset and remeasure the lease liability to reflect the partial or full

termination of the lease, and recognise the difference in profit or loss.

(17) Investment property

An investment property is stated initially at its cost and measured subsequently using the cost model. Except for land, investment property is depreciated on a straight-line basis over its estimated useful life of 60 years.

(18) Intangible assets

A. Patents

Patents is stated at cost and amortised on a straight-line basis over its estimated useful life of 5 ~ 10 years.

B. Computer software

Computer software is stated at cost and amortised on a straight-line basis over its estimated useful life of 3 ~ 10 years.

(19) Impairment of non-financial assets

A. The Company assesses at each balance sheet date the recoverable amounts of those assets where there is an indication that they are impaired. An impairment loss is recognised for the amount by which the asset's carrying amount exceeds its recoverable amount. The recoverable amount is the higher of an asset's fair value less costs to sell or value in use. Except for goodwill, when the circumstances or reasons for recognising impairment loss for an asset in prior years no longer exist or diminish, the impairment loss is reversed. The increased carrying amount due to reversal should not be more than what the depreciated or amortised historical cost would have been if the impairment had not been recognised.

B. The recoverable amounts of goodwill has not yet been available for use are evaluated periodically. An impairment loss is recognised for the amount by which the asset's carrying amount exceeds its recoverable amount. Impairment loss of goodwill previously recognised in profit or loss shall not be reversed in the following years.

C. For the purpose of impairment testing, goodwill acquired in a business combination is allocated to each of the cash-generating units, or groups of cash-generating units, that is/are expected to benefit from the synergies of the business combination. Each unit or group of units to which the goodwill is allocated represents the lowest level within the entity at which the goodwill is monitored for internal management purposes. Goodwill is monitored at the operating segment level.

(20) Borrowings

Borrowings comprise short-term bank borrowings. Borrowings are recognised initially at fair value, net of transaction costs incurred. Borrowings are subsequently stated at amortised cost; any difference between the proceeds (net of transaction costs) and the redemption value is recognised in profit or loss over the period of the borrowings using the effective interest method.

(21) Notes and accounts payable

A. Accounts payable are liabilities for purchases of raw materials, goods or services and notes

payable are those resulting from operating and non-operating activities.

- B. The short-term notes and accounts payable without bearing interest are subsequently measured at initial invoice amount as the effect of discounting is immaterial.

(22) Derecognition of financial liabilities

A financial liability is derecognised when the obligation in the contract is discharged or cancelled or expires.

(23) Employee benefits

A. Short-term employee benefits

Short-term employee benefits are measured at the undiscounted amount of the benefits expected to be paid in respect of service rendered by employees in a period and should be recognised as expenses in that period when the employees render service.

B. Pensions

(a) Defined contribution plan

For defined contribution plan, the contributions are recognised as pension expenses when they are due on an accrual basis. Prepaid contributions are recognised as an asset to the extent of a cash refund or a reduction in the future payments.

(b) Defined benefit plan

- i. Net obligation under a defined benefit plan is defined as the present value of an amount of pension benefits that employees will receive on retirement for their services with the Company in current period or prior periods. The liability recognised in the balance sheet in respect of defined benefit pension plan is the present value of the defined benefit obligation at the balance sheet date less the fair value of plan assets. The net defined benefit obligation is calculated annually by independent actuaries using the projected unit credit method. The rate used to discount is determined by using interest rates of government bonds of a currency and term consistent with the currency and term of the employment benefit obligations.
- ii. Remeasurements arising on defined benefit plans are recognised in other comprehensive income in the period in which they arise and are recorded as retained earnings.

C. Employees' compensation and directors' remuneration

Employees' compensation and directors' remuneration are recognised as expenses and liability, provided that such recognition is required under legal or constructive obligation and those amounts can be reliably estimated. Any difference between the resolved amounts and the subsequently actual distributed amounts is accounted for as changes in estimates. If employees' compensation is distributed by shares, the Company calculates the number of shares based on the closing price at the previous day of the board meeting resolution.

(24) Income tax

- A. The tax expense for the period comprises current and deferred tax. Tax is recognised in profit or loss, except to the extent that it relates to items recognised in other comprehensive income or



items recognised directly in equity, in which cases the tax is recognised in other comprehensive income or equity.

- B. The current income tax expense is calculated on the basis of the tax laws enacted or substantively enacted at the balance sheet date in the countries where the Company operate and generate taxable income. Management periodically evaluates positions taken in tax returns with respect to situations in accordance with applicable tax regulations. It establishes provisions where appropriate based on the amounts expected to be paid to the tax authorities. An additional tax is levied on the unappropriated retained earnings and is recorded as income tax expense in the year the stockholders resolve to retain the earnings.
- C. Deferred tax is recognised, using the balance sheet liability method, on temporary differences arising between the tax bases of assets and liabilities and their carrying amounts in the parent company only balance sheet. However, the deferred tax is not accounted for if it arises from initial recognition of goodwill or of an asset or liability in a transaction other than a business combination that at the time of the transaction affects neither accounting nor taxable profit or loss. Deferred tax is provided on temporary differences arising on investments in subsidiaries and associates, except where the timing of the reversal of the temporary difference is controlled by the Company and it is probable that the temporary difference will not reverse in the foreseeable future. Deferred tax is determined using tax rates and laws that have been enacted or substantially enacted by the balance sheet date and are expected to apply when the related deferred tax asset is realised or the deferred tax liability is settled.
- D. Deferred tax assets are recognised only to the extent that it is probable that future taxable profit will be available against which the temporary differences can be utilised. At each balance sheet date, unrecognised and recognised deferred tax assets are reassessed.
- E. Current income tax assets and liabilities are offset and the net amount reported in the balance sheet when there is a legally enforceable right to offset the recognised amounts and there is an intention to settle on a net basis or realise the asset and settle the liability simultaneously. Deferred tax assets and liabilities are offset on the balance sheet when the entity has the legally enforceable right to offset current tax assets against current tax liabilities and they are levied by the same taxation authority on either the same entity or different entities that intend to settle on a net basis or realise the asset and settle the liability simultaneously
- F. A deferred tax asset shall be recognised for the carryforward of unused tax credits resulting from research and development expenditures, etc., to the extent that it is possible that future taxable profit will be available against which the unused tax credits can be utilised.

(25) Share capital

Ordinary shares are classified as equity. Incremental costs directly attributable to the issue of new shares are shown in equity as a deduction, net of tax, from the proceeds.

(26) Dividends

Cash dividends are recorded as liabilities in the Company's financial statements in the period in

which they are resolved by the Board of Directors. Stock dividends are recorded as stock dividends to be distributed in which they are resolved by the Company's shareholders and are reclassified to ordinary shares on the effective date of new shares issuance.

(27) Revenue recognition

A. Sales of goods

- (a) The Company manufactures and sells human pharmaceuticals, etc. Revenue is recognised when control of the products has transferred, being when the products are delivered to the customer, the customer has full discretion over the channel and price to sell the products, and there is no unfulfilled obligation that could affect the customer's acceptance of the products. Delivery occurs when the products have been shipped to the specific location, the risks of obsolescence and loss have been transferred to the customer, and either the customer has accepted the products in accordance with the sales contract, or the Company has objective evidence that all criteria for acceptance have been satisfied.
- (b) Goods are often sold with discounts and allowances based on the price spread given by the National Health Insurance. Revenue is recognised based on the price specified in the contract, net of the estimated sales discounts and allowances. Reversal of accounts receivable is recognised for expected sales discounts and allowances payable to customers in relation to sales made until the end of the reporting period. The terms of sales transactions are set individually with each clients and usually are made with cash payment in 2 months after billings, or to obtain cheques with a maturity of 4~6 months upon billings. As the time interval between the transfer of committed goods or service and the payment of customer does not exceed one year, the Company does not adjust the transaction price to reflect the time value of money.
- (c) A receivable is recognised when the goods are delivered as this is the point in time that the consideration is unconditional because only the passage of time is required before the payment is due.

B. Rendering of services

- (a) The Company provides processing services. Revenue from providing services is recognised in the accounting period in which the services are rendered. For fixed price contracts, revenue is recognised based on the actual service provided to the end of the balance sheet date as a proportion of the total services to be provided.
- (b) The Company's estimate about revenue, costs and progress towards complete satisfaction of a performance obligation is subject to a revision whenever there is a change in circumstances. Any increase or decrease in revenue or costs due to an estimate revision is reflected in profit or loss during the period when the management become aware of the changes in circumstances.

C. Incremental costs of obtaining a contract

Given that the contractual period lasts less than one year, the Company recognises the

incremental costs of obtaining a contract as an expense when incurred although the Company expects to recover those costs.

(28) Government grants

Government grants are recognised in profit or loss on a systematic basis over the periods in which the Company recognises expenses for the related costs for which the grants are intended to compensate.

5. CRITICAL ACCOUNTING JUDGEMENTS, ESTIMATES AND KEY SOURCES OF ASSUMPTION UNCERTAINTY

The preparation of these consolidated financial statements requires management to make critical judgements in applying the Group's accounting policies and make critical assumptions and estimates concerning future events. Assumptions and estimates may differ from the actual results and are continually evaluated and adjusted based on historical experience and other factors. Such assumptions and estimates have a significant risk of causing a material adjustment to the carrying amounts of assets and liabilities within the next financial year; and the related information is addressed below:

(1) Critical judgements in applying the Company's accounting policies

None.

(2) Critical accounting estimates and assumptions

A. Valuation of inventories

- (a) As inventories are stated at the lower of cost and net realisable value, the Company must determine the net realisable value of inventories on balance sheet date using judgements and estimates. Due to the influence of different market demand and expiration date, etc., the Company evaluates the amounts of normal inventory consumption, obsolete inventories or inventories without market selling value on balance sheet date, and writes down the cost of inventories to the net realisable value. Such an evaluation of inventories is principally based on the demand for the products within the specified period in the future. Therefore, there might be material changes to the valuation.

- (b) As of December 31, 2023, the carrying amount of inventories was \$ 704,154.

B. Financial assets - fair value measurement of unlisted stocks without active market

- (a) The fair value of unlisted stocks held by the Company that are not traded in an active market is determined considering those companies' recent funding raising activities and technical development status, fair value assessment of other companies of the same type, market conditions and other economic indicators existing on balance sheet date. Any changes in these judgements and estimates will impact the fair value measurement of these unlisted stocks. Please refer to Note 12(3) for the financial instruments fair value information.

- (b) As of December 31, 2023, the carrying amount of unlisted stocks without active market was \$112,434.

## 6. DETAILS OF SIGNIFICANT ACCOUNTS

### (1) Cash and cash equivalents

	<u>December 31, 2023</u>	<u>December 31, 2022</u>
Cash:		
Revolving funds and petty cash	\$ 8,542	\$ 6,523
Checking accounts and demand deposits	<u>236,115</u>	<u>121,299</u>
	<u>244,657</u>	<u>127,822</u>
Cash equivalents:		
Time deposits	452,693	648,054
Repurchase bonds	<u>18,424</u>	<u>82,376</u>
	<u>471,117</u>	<u>730,430</u>
	<u>\$ 715,774</u>	<u>\$ 858,252</u>

- A. The Company transacts with a variety of financial institutions all with high credit quality to disperse credit risk, so it expects that the probability of counterparty default is remote.
- B. As of December 31, 2023 and 2022, the carrying amount of more than 3-month time deposits (listed as “Financial assets at amortised cost - current”) was \$8,000 and \$—, respectively.
- C. As of December 31, 2023 and 2022, the Company has no cash and cash equivalents pledged to others.

### (2) Financial assets at fair value through profit or loss

	<u>December 31, 2023</u>	<u>December 31, 2022</u>
Current items:		
Financial assets mandatorily measured at fair value through profit or loss		
Unlisted stocks	\$ 12,000	\$ 12,000
Valuation adjustment	( <u>12,000</u> )	( <u>12,000</u> )
	<u>\$ —</u>	<u>\$ —</u>
Non-current items:		
Financial assets mandatorily measured at fair value through profit or loss		
Emerging stocks	\$ 1,603	\$ 1,603
Unlisted stocks	<u>11,300</u>	<u>11,300</u>
	<u>12,903</u>	<u>12,903</u>
Valuation adjustment	( <u>1,299</u> )	( <u>2,342</u> )
	<u>\$ 11,604</u>	<u>\$ 10,561</u>

- A. The Company recognised net gain (listed as “Other gains and losses”) of \$1,043 and \$712 for the years ended December 31, 2023 and 2022, respectively.
- B. As of December 31, 2023 and 2022, the Company has no financial assets at fair value through

profit or loss pledged to others.

C. Information relating to credit risk of financial assets at fair value through profit or loss is provided in Note 12(2), 'Financial instruments'.

(3) Financial assets at fair value through other comprehensive income - non-current

	<u>December 31, 2023</u>	<u>December 31, 2022</u>
Equity instruments		
Listed stocks	\$ 129,473	\$ 163,989
Unlisted stocks	<u>63,295</u>	<u>63,295</u>
	192,768	227,284
Valuation adjustment	<u>151,069</u>	<u>21,082</u>
	<u>\$ 343,837</u>	<u>\$ 248,366</u>

A. The Company has elected to classify equity instruments that are considered to be strategic investments as financial assets at fair value through other comprehensive income. Without taking into account any collateral held or other credit enhancements, the maximum exposure to credit risk in respect of the amount that best represents the financial assets at fair value through other comprehensive income held by the Company was its book value.

B. The Company disposed financial assets at fair value through other comprehensive income in the amount of \$75,964 and \$23,305 for the years ended December 31, 2023 and 2022, respectively. This resulted in cumulative gain on disposal amounting to \$22,465 and \$5,958, which was reclassified to retained earnings for the years ended December 31, 2023 and 2022, respectively.

C. The Company recognised \$152,452 and (\$14,235) in other comprehensive income in relation to fair value change for the years ended December 31, 2023 and 2022, respectively.

D. The Company recognised dividend income of \$10,034 and \$9,604 in profit or loss (listed as 'Other income') in relation to the financial assets at fair value through other comprehensive income for the years ended December 31, 2023 and 2022, respectively.

E. As of December 31, 2023 and 2022, the Company has no financial assets at fair value through other comprehensive income pledged to others.

F. Information relating to credit risk of financial assets at fair value through other comprehensive income is provided in Note 12(2), 'Financial instruments'.

(4) Notes and accounts receivable

	<u>December 31, 2023</u>	<u>December 31, 2022</u>
Notes receivable	<u>\$ 109,055</u>	<u>\$ 100,411</u>
Accounts receivable	\$ 582,942	\$ 537,951
Less: Allowance for uncollectible accounts	<u>( 4,537)</u>	<u>( 4,256)</u>
	<u>\$ 578,405</u>	<u>\$ 533,695</u>

A. The ageing analysis of notes and accounts receivable is as follows:

	<u>December 31, 2023</u>	<u>December 31, 2022</u>
Notes receivable:		
Within the credit period	\$ <u>109,055</u>	\$ <u>100,411</u>
Accounts receivable:		
Within the credit period	\$ 567,416	\$ 501,902
Overdue up to 90 days	15,290	14,596
Overdue 91 to 180 days	212	21,451
Overdue 181 to 270 days	–	2
Overdue over 270 days	<u>24</u>	<u>–</u>
	<u>\$ 582,942</u>	<u>\$ 537,951</u>

The above ageing analysis was based on days overdue.

- B. As of December 31, 2023 and 2022, notes and accounts receivable were all from contracts with customers. As of January 1, 2022, the balance of receivables from contracts with customers amounted to \$645,559.
- C. Without taking into account any collateral held or other credit enhancements, the maximum exposure to credit risk in respect of the amount that best represents the Company's notes and accounts receivable were its book value.
- D. As of December 31, 2023 and 2022, the Company has no notes and accounts receivable pledged to others.
- E. Information relating to credit risk of notes and accounts receivable is provided in Note 12(2), 'Financial instruments'.

(5) Other receivables

	<u>December 31, 2023</u>	<u>December 31, 2022</u>
Claims receivable	\$ –	\$ 61,693
Others	<u>11,314</u>	<u>10,597</u>
	<u>\$ 11,314</u>	<u>\$ 72,290</u>

(Note) The Company was affected by the fire incident in the neighbouring subsidiary – Syn-Tech Chem & Pharm Co., Ltd. (Syn-Tech) on May 20, 2021, which resulted in the damage of certain property, plant and equipment, and inventories and therefore interrupting part of the operations. The Company had derecognised some damaged property, plant and equipment and inventories amounting to \$61,693 and \$4,608, respectively. The total loss as a result of the fire incident was \$66,301 for the year ended December 31, 2021.

The Company had obtained property insurance for its property, plant and equipment. The Company has inspected some purchasing contract of the assets and after consideration of Consumer Price Index, calculated the replacement cost that could be covered by the insurance based on external information. The Company recognised indemnity income at \$66,301 limited to the loss of each property for the year ended December 31, 2021. The insurance company

had checked the damaged property in June 2023 and paid insurance claims in the amount of \$109,132. The Company recognised the difference of \$42,831 between the actual indemnity income and original estimated insurance claims as fire claims income (Listed as “Other income”) in 2023.

(6) Inventories

December 31, 2023			
	Cost	Allowance for valuation loss	Book value
Merchandise	\$ 49,060	(\$ 25)	\$ 49,035
Raw materials	225,052	( 5,550)	219,502
Supplies	42,447	( 1,044)	41,403
Work in process	75,717	( 842)	74,875
Finished goods	328,267	( 8,928)	319,339
	<u>\$ 720,543</u>	<u>(\$ 16,389)</u>	<u>\$ 704,154</u>
December 31, 2022			
	Cost	Allowance for valuation loss	Book value
Merchandise	\$ 48,366	(\$ 44)	\$ 48,322
Raw materials	185,304	( 2,861)	182,443
Supplies	37,174	( 550)	36,624
Work in process	76,836	–	76,836
Finished goods	227,347	( 9,174)	218,173
	<u>\$ 575,027</u>	<u>(\$ 12,629)</u>	<u>\$ 562,398</u>

The cost of inventories recognised as expenses for the year:

	For the years ended December 31,	
	2023	2022
Cost of goods sold	\$ 1,483,859	\$ 1,443,966
Loss on scrapped inventories	10,615	13,673
Provision (reversal of allowance) for inventory market price decline (Note)	3,760 (	3,807)
Gain on physical inventory	( 985)	( 741)
	<u>\$ 1,497,249</u>	<u>\$ 1,453,091</u>

(Note) For the year ended December 31, 2022, the Company reversed a previous inventory write-down which was accounted for as reduction of operating costs as these items were subsequently sold or disposed.

(7) Investments accounted for under equity method

A. Movements of investments accounted for under equity method:

	For the years ended December 31,	
	2023	2022
At January 1	\$ 2,820,888	\$ 2,413,208
Acquisition of investments accounted for under equity method (Note)	5,578	260,190
Disposal of investments accounted for under equity method	— (	9,156)
Share of profit or loss of investments accounted for under equity method	202,268	205,039
Earnings distribution of investments accounted for under equity method	( 101,283)	( 74,066)
Capital surplus — Difference between the price for acquisition or disposal of subsidiaries and carrying amount	—	3,521
Capital surplus — Changes in net equity of associates and joint ventures accounted for under equity method	3,281	3,744
Capital surplus — Overdue cash dividends payable of subsidiaries	65	46
Other equity interest — Financial statements translation differences of foreign operations	( 970)	14,492
Other equity interest — Unrealised gain or loss on valuation of financial assets	95	95
Retained earnings — Remeasurement of defined benefit plan	400	3,775
At December 31	<u>\$ 2,930,322</u>	<u>\$ 2,820,888</u>
	<u>December 31, 2023</u>	<u>December 31, 2022</u>
Subsidiaries	\$ 2,654,123	\$ 2,553,404
Associates	276,199	267,484
	<u>\$ 2,930,322</u>	<u>\$ 2,820,888</u>

(Note) The Company implements its work-division and resource integration, to enhance competitiveness and business performance through spin-off of its synthesis department to its subsidiary — Syn-Tech Chem & Pharm Co., Ltd. (Syn-Tech) after the resolution by the Board of Directors on March 16, 2021. The Company will receive newly issued common stock of Syn-Tech as consideration. The effective date was set on July 1, 2022. The information on the effective date is as follows:



	<u>July 1, 2022</u>
Assets acquired from spin-off:	
Cash	\$ 6, 973
Investments accounted for under equity method	<u>208, 627</u>
	<u>\$ 215, 600</u>
Identifiable assets and liabilities of the synthesis department:	
Inventories	\$ 29, 790
Other current assets	19, 926
Property, plant and equipment	119, 962
Other non-current assets	60, 163
Current liabilities	( <u>22, 976</u> )
	<u>\$ 206, 865</u>
Difference between consideration received and identifiable net asset under spin-off (Listed as "Capital surplus - additional paid-in capital")	<u>\$ 8, 735</u>

B. Details of investments accounted for under equity method are as follows:

	<u>December 31, 2023</u>	<u>December 31, 2022</u>
Standard Pharmaceutical Co., Ltd.	\$ 179, 272	\$ 181, 720
Chia Scheng International Co., Ltd. (Note)	11, 363	11, 003
Standard Chem. & Pharm. Philippines, Inc.	3, 996	314
Inforight Technology Co., Ltd.	7, 666	4, 212
Souriree Biotech & Pharm. Co., Ltd.	50, 404	41, 483
Multipower Enterprise Corp.	324, 570	337, 397
Advpharma Inc.	271, 699	266, 798
Syngen Biotech Co., Ltd.	975, 993	910, 035
Syn-Tech Chem. & Pharm. Co., Ltd.	784, 589	758, 751
Ho Yao Biopharm Co., Ltd.	43, 286	38, 417
Shanghai Standard Pharmaceuticals Co., Ltd.	1, 285	3, 274
We Can Medicines Co., Ltd.	243, 423	235, 502
Taiwan Biosim Co., Ltd.	<u>32, 776</u>	<u>31, 982</u>
	<u>\$ 2, 930, 322</u>	<u>\$ 2, 820, 888</u>

(Note) Formerly named as 'Chia Scheng Investment Co., Ltd.' and the name was changed since October 12, 2023.

C. Information on the Company's subsidiaries is provided in Note 4(3) of the Company's 2023 consolidated financial statements.

D. Associate:

(a) The basic information of the associate that is material to the Company is as follows:

Company name	Principal place of business	Shareholding ratio	
		December 31,	
		2023	2022
We Can Medicines Co., Ltd.	Taiwan	32.89%	32.89%

(b) The summarised financial information of the associate that is material to the Company is as follows:

i. Balance sheets

	December 31, 2023	December 31, 2022
Current assets	\$ 1,291,531	\$ 1,154,634
Non-current assets	1,569,322	1,421,200
Current liabilities	( 1,045,095)	( 900,340)
Non-current liabilities	( 999,411)	( 883,805)
Total net assets	<u>\$ 816,347</u>	<u>\$ 791,689</u>
Share in associate's net assets	\$ 268,497	\$ 260,387
Unrealised gain from transactions with associate	( 25,074)	( 24,885)
Carrying amount of the associate	<u>\$ 243,423</u>	<u>\$ 235,502</u>

ii. Statements of comprehensive income

	For the years ended December 31,	
	2023	2022
Revenue	<u>\$ 3,122,894</u>	<u>\$ 3,302,732</u>
Net income for the year	<u>\$ 14,803</u>	<u>\$ 100,054</u>
Total comprehensive income for the year	<u>\$ 14,683</u>	<u>\$ 103,045</u>

(c) As of December 31, 2023 and 2022, the carrying amount of the Company's individually immaterial associates amounted to \$ 32,776 and \$31,982, respectively. The share in associate's financial performance is as follows:

	For the years ended December 31,	
	2023	2022
Net income for the year	<u>\$ 794</u>	<u>\$ 1,370</u>
Total comprehensive income for the year	<u>\$ 794</u>	<u>\$ 1,370</u>

E. For the years ended December 31, 2023 and 2022, the details of the Company's equity transactions are provided in Note 7, "Related party transactions".

F. As of December 31, 2023 and 2022, the Company has no investments accounted for under equity method pledged to others.

(8) Property, plant and equipment

	Land	Buildings	Machinery	Utility equipment	Transportation equipment	Office equipment	Other equipment	Construction in process	Total
<u>At January 1, 2023</u>									
Cost	\$ 321,069	\$ 934,290	\$ 808,676	\$ 136,153	\$ 17,914	\$ 35,813	\$ 341,099	\$ 12,788	\$ 2,607,802
Accumulated depreciation	–	( 572,042)	( 667,360)	( 114,427)	( 14,512)	( 27,625)	( 208,781)	–	( 1,604,747)
	<u>\$ 321,069</u>	<u>\$ 362,248</u>	<u>\$ 141,316</u>	<u>\$ 21,726</u>	<u>\$ 3,402</u>	<u>\$ 8,188</u>	<u>\$ 132,318</u>	<u>\$ 12,788</u>	<u>\$ 1,003,055</u>
<u>For the year ended December 31, 2023</u>									
At January 1	\$ 321,069	\$ 362,248	\$ 141,316	\$ 21,726	\$ 3,402	\$ 8,188	\$ 132,318	\$ 12,788	\$ 1,003,055
Additions-cost	–	9,263	13,439	784	1,115	3,301	4,256	22,972	55,130
Transfer-cost (Note 1)	–	30,735	16,819	212	( 30)	249	14,420	( 29,424)	32,981
-accumulated depreciation (Note 1)	–	–	–	–	70	( 70)	–	–	–
Depreciation	–	( 25,100)	( 38,244)	( 6,102)	( 1,042)	( 2,441)	( 23,619)	–	( 96,548)
Disposals-cost	–	( 2,752)	( 869)	( 481)	( 284)	( 816)	( 4,200)	–	( 9,402)
-accumulated depreciation	–	2,752	869	481	284	816	4,200	–	9,402
At December 31	<u>\$ 321,069</u>	<u>\$ 377,146</u>	<u>\$ 133,330</u>	<u>\$ 16,620</u>	<u>\$ 3,515</u>	<u>\$ 9,227</u>	<u>\$ 127,375</u>	<u>\$ 6,336</u>	<u>\$ 994,618</u>
<u>At December 31, 2023</u>									
Cost	\$ 321,069	\$ 971,536	\$ 838,065	\$ 136,668	\$ 18,715	\$ 38,547	\$ 355,575	\$ 6,336	\$ 2,686,511
Accumulated depreciation	–	( 594,390)	( 704,735)	( 120,048)	( 15,200)	( 29,320)	( 228,200)	–	( 1,691,893)
	<u>\$ 321,069</u>	<u>\$ 377,146</u>	<u>\$ 133,330</u>	<u>\$ 16,620</u>	<u>\$ 3,515</u>	<u>\$ 9,227</u>	<u>\$ 127,375</u>	<u>\$ 6,336</u>	<u>\$ 994,618</u>

(Note 1) Including transfer of \$35,115 from “Prepayments for equipment” and transfer of \$2,134 to “Expense”.

	Land	Buildings	Machinery	Utility equipment	Transportation equipment	Office equipment	Other equipment	Construction in process	Total
At January 1, 2022									
Cost	\$ 314,060	\$ 890,918	\$ 848,038	\$ 148,329	\$ 20,579	\$ 33,981	\$ 328,932	\$ 33,815	\$ 2,618,652
Accumulated depreciation	–	( 572,212)	( 692,601)	( 116,688)	( 15,422)	( 26,009)	( 229,306)	–	( 1,652,238)
	<u>\$ 314,060</u>	<u>\$ 318,706</u>	<u>\$ 155,437</u>	<u>\$ 31,641</u>	<u>\$ 5,157</u>	<u>\$ 7,972</u>	<u>\$ 99,626</u>	<u>\$ 33,815</u>	<u>\$ 966,414</u>
For the year ended December 31, 2022									
At January 1	\$ 314,060	\$ 318,706	\$ 155,437	\$ 31,641	\$ 5,157	\$ 7,972	\$ 99,626	\$ 33,815	\$ 966,414
Additions-cost	90	15,445	13,262	–	909	1,434	45,538	95,115	171,793
Transfer-cost (Note 1)	6,919	64,804	23,699	–	–	894	12,891	( 33,051)	76,156
-accumulated depreciation (Note 1)	–	1,148	–	–	–	–	–	–	1,148
Depreciation	–	( 27,080)	( 34,289)	( 6,346)	( 1,271)	( 1,975)	( 19,698)	–	( 90,659)
Spin-off -cost (Note 2)	–	( 24,620)	( 64,230)	( 12,176)	( 3,140)	( 282)	( 31,792)	( 83,091)	( 219,331)
-accumulated depreciation (Note 2)	–	14,449	48,171	8,607	1,747	145	26,250	–	99,369
Disposals-cost	–	( 12,257)	( 12,093)	–	( 434)	( 214)	( 14,470)	–	( 39,468)
-accumulated depreciation	–	11,653	11,359	–	434	214	13,973	–	37,633
At December 31	<u>\$ 321,069</u>	<u>\$ 362,248</u>	<u>\$ 141,316</u>	<u>\$ 21,726</u>	<u>\$ 3,402</u>	<u>\$ 8,188</u>	<u>\$ 132,318</u>	<u>\$ 12,788</u>	<u>\$ 1,003,055</u>
At December 31, 2022									
Cost	\$ 321,069	\$ 934,290	\$ 808,676	\$ 136,153	\$ 17,914	\$ 35,813	\$ 341,099	\$ 12,788	\$ 2,607,802
Accumulated depreciation	–	( 572,042)	( 667,360)	( 114,427)	( 14,512)	( 27,625)	( 208,781)	–	( 1,604,747)
	<u>\$ 321,069</u>	<u>\$ 362,248</u>	<u>\$ 141,316</u>	<u>\$ 21,726</u>	<u>\$ 3,402</u>	<u>\$ 8,188</u>	<u>\$ 132,318</u>	<u>\$ 12,788</u>	<u>\$ 1,003,055</u>

(Note 1) Including transfer of \$94,299 from “Prepayments for equipment” and transfer of \$16,995 to “Investment property, net”.

(Note 2) Refer to Note 6(7), “Investments accounted for under equity method”.

A. As of December 31, 2023 and 2022, the carrying amount of buildings held for operating leases are as follows:

	<u>December 31, 2023</u>	<u>December 31, 2022</u>
Buildings	<u>\$ 81</u>	<u>\$ 84</u>

B. Amount of borrowing costs capitalised as part of property, plant and equipment and the interest rates for such capitalisation for the years ended December 31, 2023 and 2022 are as follows:

	<u>For the years ended December 31,</u>	
	<u>2023</u>	<u>2022</u>
Capitalised interest payments	<u>\$ 374</u>	<u>\$ 638</u>
Interest rate	<u>1.42%~1.77%</u>	<u>0.73%~1.02%</u>

C. Refer to Note 6(7), 'Investments accounted for under equity method' for more information regarding property, plant and equipment transferred due to spin-off of synthesis department in July 2022.

D. As of December 31, 2023 and 2022, the Company has no property, plant and equipment pledged to others.

(9) Leasing arrangements — lessee

A. The Company leases various assets including land and buildings. Rental contracts are typically made for periods of 2 ~ 11 years. Lease terms are negotiated on an individual basis and contain a wide range of different terms and conditions. The lease agreements do not impose covenants.

B. The carrying amount of right-of-use assets and the depreciation are as follows:

	<u>December 31, 2023</u>	<u>December 31, 2022</u>
	<u>Carrying amount</u>	<u>Carrying amount</u>
Land	\$ 3,063	\$ 3,449
Buildings	9,035	12,262
Transportation equipment	878	—
	<u>\$ 12,976</u>	<u>\$ 15,711</u>
	<u>For the years ended December 31,</u>	
	<u>2023</u>	<u>2022</u>
	<u>Depreciation</u>	<u>Depreciation</u>
Land	\$ 1,005	\$ 1,005
Buildings	4,084	3,762
Transportation equipment	265	—
	<u>\$ 5,354</u>	<u>\$ 4,767</u>

C. The additions to right-of-use assets were \$2,619 and \$2,725 for the years ended December 31, 2023 and 2022, respectively.

D. The information on profit and loss accounts relating to lease contracts is as follows:

	For the years ended December 31,	
	2023	2022
<u>Items affecting profit or loss</u>		
Interest expense on lease liabilities	\$ 169	\$ 197
Expense on short-term lease contract	535	391
Expense on leases of low-value assets	240	458
Gain from lease modification	– (	8)

E. The Company's total cash outflow for leases was \$6,334 and \$5,888 for the years ended December 31, 2023 and 2022, respectively.

(10) Investment property, net

	Land	Buildings	Total
<u>At January 1, 2023</u>			
Cost	\$ 59,483	\$ 8,731	\$ 68,214
Accumulated depreciation	–	( 5,227)	( 5,227)
	<u>\$ 59,483</u>	<u>\$ 3,504</u>	<u>\$ 62,987</u>
<u>For the year ended December 31, 2023</u>			
At January 1	\$ 59,483	\$ 3,504	\$ 62,987
Depreciation	–	( 214)	( 214)
At December 31	<u>\$ 59,483</u>	<u>\$ 3,290</u>	<u>\$ 62,773</u>
<u>At December 31, 2023</u>			
Cost	\$ 59,483	\$ 8,731	\$ 68,214
Accumulated depreciation	–	( 5,441)	( 5,441)
	<u>\$ 59,483</u>	<u>\$ 3,290</u>	<u>\$ 62,773</u>

	Land	Buildings	Total
<u>At January 1, 2022</u>			
Cost	\$ 43,295	\$ 6,776	\$ 50,071
Accumulated depreciation	–	( 3,864)	( 3,864)
	<u>\$ 43,295</u>	<u>\$ 2,912</u>	<u>\$ 46,207</u>
<u>For the year ended December 31, 2022</u>			
At January 1	\$ 43,295	\$ 2,912	\$ 46,207
Transfer-cost (Note)	16,188	1,955	18,143
-accumulated depreciation (Note)	–	( 1,148)	( 1,148)
Depreciation	–	( 215)	( 215)
At December 31	<u>\$ 59,483</u>	<u>\$ 3,504</u>	<u>\$ 62,987</u>
<u>At December 31, 2022</u>			
Cost	\$ 59,483	\$ 8,731	\$ 68,214
Accumulated depreciation	–	( 5,227)	( 5,227)
	<u>\$ 59,483</u>	<u>\$ 3,504</u>	<u>\$ 62,987</u>

(Note) Transferred from “Property, plant and equipment”.

A. Rental income from investment property (listed as “Other income”) and direct operating expenses arising from investment property are as follows:

	For the years ended December 31,	
	2023	2022
Rental income from investment property	<u>\$ 5,746</u>	<u>\$ 5,189</u>
Direct operating expenses of investment properties with rental income	<u>\$ 214</u>	<u>\$ 215</u>

B. The fair value of the investment property held by the Company as of December 31, 2023 and 2022 was \$ 116,501 and \$116,656, respectively, which was valued from the actual real estate price registered on the Department of Land Administration website. The valuation is categorised within Level 2 in the fair value hierarchy.

C. No borrowing costs were capitalised as part of investment property for the years ended December 31, 2023 and 2022.

D. As of December 31, 2023 and 2022, the Company has no investment property pledged to others.

(11) Intangible assets

	Patents	Software	Total
<u>At January 1, 2023</u>			
Cost	\$ 11,202	\$ 33,378	\$ 44,580
Accumulated amortisation	( 10,576)	( 27,630)	( 38,206)
	<u>\$ 626</u>	<u>\$ 5,748</u>	<u>\$ 6,374</u>
<u>For the year ended December 31, 2023</u>			
At January 1	\$ 626	\$ 5,748	\$ 6,374
Additions - acquired separately	–	817	817
Amortisation	( 597)	( 2,434)	( 3,031)
At December 31	<u>\$ 29</u>	<u>\$ 4,131</u>	<u>\$ 4,160</u>
<u>At December 31, 2023</u>			
Cost	\$ 11,202	\$ 34,195	\$ 45,397
Accumulated amortisation	( 11,173)	( 30,064)	( 41,237)
	<u>\$ 29</u>	<u>\$ 4,131</u>	<u>\$ 4,160</u>
	Patents	Software	Total
<u>At January 1, 2022</u>			
Cost	\$ 11,602	\$ 29,814	\$ 41,416
Accumulated amortisation	( 10,110)	( 24,681)	( 34,791)
	<u>\$ 1,492</u>	<u>\$ 5,133</u>	<u>\$ 6,625</u>
<u>For the year ended December 31, 2022</u>			
At January 1	\$ 1,492	\$ 5,133	\$ 6,625
Additions-acquired separately	–	3,564	3,564
Amortisation	( 866)	( 2,949)	( 3,815)
Spin-off-cost	( 400)	–	( 400)
-accumulated amortisation	<u>400</u>	<u>–</u>	<u>400</u>
At December 31	<u>\$ 626</u>	<u>\$ 5,748</u>	<u>\$ 6,374</u>
<u>At December 31, 2022</u>			
Cost	\$ 11,202	\$ 33,378	\$ 44,580
Accumulated amortisation	( 10,576)	( 27,630)	( 38,206)
	<u>\$ 626</u>	<u>\$ 5,748</u>	<u>\$ 6,374</u>

A. No borrowing costs were capitalised as part of intangible assets for the years ended December 31, 2023 and 2022.



B. Details of amortisation on intangible assets are as follows:

	For the years ended December 31,	
	2023	2022
Operating costs	\$ 255	\$ 226
Selling expenses	587	895
General and administrative expenses	1, 907	2, 498
Research and development expenses	282	196
	<u>\$ 3, 031</u>	<u>\$ 3, 815</u>

C. As of December 31, 2023 and 2022, the Company has no intangible assets pledged to others.

(12) Short-term borrowings

	December 31, 2023	Interest rate range	Collateral
Unsecured bank borrowings	<u>\$ 460, 000</u>	1. 58%~1. 66%	None
	December 31, 2022	Interest rate range	Collateral
Unsecured bank borrowings	<u>\$ 870, 000</u>	1. 36%~1. 78%	None

Refer to Note 6(22), 'Finance costs' for more information regarding interest expenses recognised in profit or loss by the Company for the years ended December 31, 2023 and 2022.

(13) Pensions

A. The Company has a defined benefit pension plan in accordance with the Labour Standards Law, covering all regular employees' service years prior to the enforcement of the Labour Pension Act on July 1, 2005 and service years thereafter of employees who chose to continue to be subject to the pension mechanism under the Law. Under the defined benefit pension plan, two units are accrued for each year of service for the first 15 years and one unit for each additional year thereafter, subject to a maximum of 45 units. Pension benefits are based on the number of units accrued and the average monthly salaries and wages of the last 6 months prior to retirement. The Company contributes monthly an amount equal to 5% of the employees' monthly salaries and wages to the retirement fund deposited with Bank of Taiwan, the trustee, under the name of the independent retirement fund committee. Also, the Company would assess the balance in the aforementioned labour pension reserve account by December 31, every year. If the account balance is insufficient to pay the pension calculated by the aforementioned method to the employees expected to qualify for retirement in the following year, the Company will make contributions for the deficit by next March. Related information of pension paid under aforementioned plan is as follows:

(a) The amounts recognised in the balance sheet are as follows:

	<u>December 31, 2023</u>	<u>December 31, 2022</u>
Present value of defined benefit obligations	(\$ 431,132)	(\$ 450,254)
Fair value of plan assets	<u>292,075</u>	<u>302,484</u>
Net defined benefit liability – non-current	<u>(\$ 139,057)</u>	<u>(\$ 147,770)</u>

(b) Movements in defined benefit liability are as follows:

	<u>Present value of defined benefit obligation</u>	<u>Fair value of plan assets</u>	<u>Net defined benefit liability</u>
For the year ended December 31, 2023			
At January 1	(\$ 450,254)	\$ 302,484	(\$ 147,770)
Current service cost	( 5,926)	–	( 5,926)
Interest (expense) income	( 5,487)	3,699	( 1,788)
Effect of pension plan curtailment	<u>243</u>	<u>–</u>	<u>243</u>
	<u>( 461,424)</u>	<u>306,183</u>	<u>( 155,241)</u>
Remeasurements:			
Return on plan assets (excluding amounts included in interest income or expense)	–	2,761	2,761
Change in financial assumptions	( 1,776)	–	( 1,776)
Experience adjustments	<u>1,910</u>	<u>–</u>	<u>1,910</u>
	<u>134</u>	<u>2,761</u>	<u>2,895</u>
Pension fund contribution	<u>–</u>	<u>9,159</u>	<u>9,159</u>
Paid pension	<u>30,158</u>	<u>( 26,028)</u>	<u>4,130</u>
At December 31	<u>(\$ 431,132)</u>	<u>\$ 292,075</u>	<u>(\$ 139,057)</u>

	Present value of defined benefit obligation	Fair value of plan assets	Net defined benefit liability
For the year ended December 31, 2022			
At January 1	(\$ 494,867)	\$ 298,533	(\$ 196,334)
Current service cost	( 3,558)	–	( 3,558)
Interest (expense) income	( 3,420)	2,081	( 1,339)
Effect of pension plan curtailment	725	–	725
Effect of pension plan settlement	4,713	–	4,713
	( 496,407)	300,614	( 195,793)
Remeasurements:			
Return on plan assets (excluding amounts included in interest income or expense)	–	23,254	23,254
Change in financial assumptions	24,483	–	24,483
Experience adjustments	( 19,822)	–	( 19,822)
	4,661	23,254	27,915
Pension fund contribution	–	12,454	12,454
Paid pension	41,492	( 33,838)	7,654
At December 31	(\$ 450,254)	\$ 302,484	(\$ 147,770)

- (c) The Bank of Taiwan was commissioned to manage the Fund of the Company's defined benefit pension plan in accordance with the Fund's annual investment and utilisation plan and the "Regulations for Revenues, Expenditures, Safeguard and Utilisation of the Labour Retirement Fund" (Article 6: The scope of utilisation for the Fund includes deposit in domestic or foreign financial institutions, investment in domestic or foreign listed, over-the-counter, or private placement equity securities, investment in domestic or foreign real estate securitisation products, etc.). With regard to the utilisation of the Fund, its minimum earnings in the annual distributions on the final financial statements shall be no less than the earnings attainable from the amounts accrued from two-year time deposits with the interest rates offered by local banks. If the earnings is less than aforementioned rates, government shall make payment for the deficit after being authorised by the Regulator. The Company has no right to participate in managing and operating that fund and hence the Company is unable to disclose the classification of plan asset fair value in accordance with IAS 19 paragraph 142. The fair value of plan assets as of December 31, 2023 and 2022 is given in the Annual Labour Retirement Fund Utilisation Report announced by the government.

(d) The principal actuarial assumptions used were as follows:

	For the years ended December 31,	
	2023	2022
Discount rate	1.20%	1.25%
Future salary increases	2.90%	2.90%

For the years ended December 31, 2023 and 2022, assumptions regarding future mortality rate are both set based on the 6th Taiwan Standard Ordinary Experience Mortality Table.

Because the main actuarial assumption changed, the present value of defined benefit obligation is affected. The analysis was as follows:

	Discount rate		Future salary increases	
	Increase 0.25%	Decrease 0.25%	Increase 0.25%	Decrease 0.25%
<u>December 31, 2023</u>				
Effect on present value of defined benefit obligation	(\$ 8,761)	\$ 9,031	\$ 8,858	(\$ 8,639)
<u>December 31, 2022</u>				
Effect on present value of defined benefit obligation	(\$ 9,652)	\$ 9,963	\$ 9,777	(\$ 9,522)

The sensitivity analysis above is based on one assumption which changed while the other conditions remain unchanged. In practice, more than one assumption may change all at once. The method of analysing sensitivity and the method of calculating net pension liability in the balance sheet are the same.

The methods and types of assumptions used in preparing the sensitivity analysis did not change compared to the previous year.

(e) Expected contributions to the defined benefit pension plan of the Company for the year ending December 31, 2024 amount to \$ 9,182.

(f) As of December 31, 2023, the weighted average duration of that retirement plan is 8 years. The analysis of timing of the future pension payment was as follows:

Within 1 year	\$ 16,702
2-5 years	113,263
Over 5 years	345,611
	<u>\$ 475,576</u>

B. Effective July 1, 2005, the Company has established a defined contribution pension plan (the “New Plan”) under the Labour Pension Act (the “Act”), covering all regular employees with R.O.C. nationality. Under the New Plan, the Company contributes monthly an amount based on 6% of the employees’ monthly salaries and wages to the employees’ individual pension accounts at the Bureau of Labour Insurance. The benefits accrued are paid monthly or in lump sum upon

termination of employment. The pension costs under the defined contribution pension plan of the Company for the years ended December 31, 2023 and 2022 were \$25,959 and \$24,137, respectively.

(14) Share capital – common stock

- A. Movements in the number of the Company's ordinary shares outstanding are as follows (in thousands of shares):

	For the years ended December 31,	
	2023	2022
Beginning and ending balance	178, 696	178, 696

- B. As of December 31, 2023, the Company's authorised capital was \$2,000,000, and the paid-in capital was \$1,786,961, consisting of 178,696 thousand shares of ordinary share, with a par value of \$10 (in dollars) per share. Shares can be issued several times. All proceeds from shares issued have been collected.

(15) Capital surplus

- A. Pursuant to the R.O.C. Company Act, capital surplus arising from paid-in capital in excess of par value on issuance of common stocks and donations can be used to cover accumulated deficit or to issue new stocks or cash to shareholders in proportion to their share ownership, provided that the Company has no accumulated deficit. Further, the R.O.C. Securities and Exchange Act requires that the amount of capital surplus to be capitalised mentioned above should not exceed 10% of the paid-in capital each year. Capital surplus should not be used to cover accumulated deficit unless the legal reserve is insufficient.
- B. The Company implements its work-division and resource integration, to enhance competitiveness and business performance through spin-off of its synthesis department to the subsidiary – Syn-Tech Chem & Pharm Co., Ltd. (Syn-Tech) after the resolution by the Board of Directors on March 16, 2021. The Company received 4,532 thousand shares issued from the capital increase of Syn-Tech with total value of \$341,000 as the consideration. The transaction pertains to the reorganisation within the Group. As the difference between the net asset value of the synthesis department and net equity value was \$8,735, an increase in capital surplus was recognised. The abovementioned transaction had been completed on July 1, 2022.
- C. As the Company's associate, We Can Medicines Co., Ltd., issued employee stock options resulting in changes in net equity. The Company recognised the increase in net equity proportionately to its ownership amounting to \$3,281 and \$1,351 for the years ended December 31, 2023 and 2022, respectively.
- D. For the year ended December 31, 2022, the investment accounted for under equity method of the Company's subsidiary, Geneferm Biotechnology Co., Ltd., exercised employee stock options resulting in an increase in the equity to Syngen Biotech Co., Ltd.. The Company recognised the increase in equity proportionately of \$2,393 and was recorded under capital surplus. There was no such transaction for the year ended December 31, 2023.

- E. For the years ended December 31, 2023 and 2022, pursuant to the Business letter No. 10602420200 issued by the Ministry of Economic Affairs, the Company reclassified dividends payable of \$56 and \$125, respectively, which were expired and not collected by the shareholders, to capital surplus. For the years ended December 31, 2023 and 2022, pursuant to the aforementioned letter, the subsidiary of the Company, Syngen Biotech Co., Ltd., reclassified dividends payable of \$140 and \$98, respectively, which were expired and not collected by the shareholders, to capital surplus, resulting to an increase in the equity attributable to owners of parent by \$65 and \$46, respectively.
- F. Refer to Note 6(27), 'Transactions with non-controlling interest' for more information regarding changes of capital surplus due to transactions with non-controlling interest.

(16) Retained earnings

- A. Within the limit, except for covering accumulated deficit or issuing new stocks or cash to shareholders in proportion to their share ownership, the legal reserve shall not be used for any other purpose. The use of legal reserve for the issuance of stocks or cash to shareholders in proportion to their share ownership is permitted, provided that the distribution of the reserve is limited to the portion in excess of 25% of the Company's paid-in-capital.
- B. Under the Company's Articles of Incorporation, as the Company operates in a volatile business environment and is in the stable growth stage, the Board of Directors takes into consideration the Company's future capital needs, long-term financial planning and shareholders' needs for cash inflow. The Company's earnings, if any, are distributed in the following order:
- (a) Pay all taxes.
  - (b) Cover accumulated deficit.
  - (c) Appropriate 10% as legal reserve, until such legal reserve amounts to the total paid-in capital.
  - (d) Appropriate or reverse special reserve in accordance with regulations.
  - (e) At least 10% of the remainder and previous unappropriated retained earnings as stockholders' bonus and cash dividends shall account for at least 20% of total dividends distributed. If the cash dividend is below \$0.5 (in dollars) per share, the Company can distribute stock dividends instead of cash dividends upon resolution of the shareholders.

When the shareholders bonus is distributed in stock dividend, it shall be allocated according to the resolutions of the shareholders during their meeting. The company authorised the Board of Directors to process resolution resolved by a majority vote at the meeting attended by two-thirds of the total number of directors: all or part of distributed dividends and bonus, and capital reserve/legal surplus reserve shall be distributed by cash. The result shall be reported to the shareholders' meeting.

- C. In accordance with the regulations, the Company shall set aside special reserve from the debit balance on other equity items at the balance sheet date before distributing earnings. When debit balance on other equity items is reversed subsequently, the reversed amount could be included in the distributable earnings. The Company's debit balance on other equity items as of

December 31, 2022 and 2021 were \$115,935 and \$110,329, respectively, which have been set aside as special reserve in accordance with the regulations and shall not be distributed as dividends.

D. As resolved by the Board of Directors on March 15, 2022 and March 14, 2023, the Company recognised cash dividends distributed to owners amounting to \$446,740 (\$2.5 (in dollars) per share) and \$446,740 (\$2.5 (in dollars) per share) for the appropriations of 2021 and 2022 earnings, respectively. On February 27, 2024, the Board of Directors resolved for the distribution of dividends from 2023 earnings of \$482,479 (\$2.7 (in dollars) per share). Information about the distribution of dividends by the Company as proposed by the Board of Directors will be posted in the “Market Observation Post System” at the website of the Taiwan Stock Exchange.

(17) Other equity

For the year ended December 31, 2023			
	Currency translation	Unrealised gain on valuation of financial assets	Total
At January 1	(\$ 6,482)	(\$ 109,453)	(\$ 115,935)
Currency translation differences			
- Company	( 970)	-	( 970)
Valuation adjustment			
- Company	-	152,452	152,452
- Subsidiaries	-	95	95
Valuation adjustment transferred to retained earnings			
- Company	-	( 22,465)	( 22,465)
At December 31	<u>(\$ 7,452)</u>	<u>\$ 20,629</u>	<u>\$ 13,177</u>
For the year ended December 31, 2022			
	Currency translation	Unrealised gain on valuation of financial assets	Total
At January 1	(\$ 20,974)	(\$ 89,355)	(\$ 110,329)
Currency translation differences			
- Company	14,492	-	14,492
Valuation adjustment			
- Company	-	( 14,235)	( 14,235)
- Subsidiaries	-	95	95
Valuation adjustment transferred to retained earnings			
- Company	-	( 5,958)	( 5,958)
At December 31	<u>(\$ 6,482)</u>	<u>(\$ 109,453)</u>	<u>(\$ 115,935)</u>

(18) Operating revenue

A. The Company derives revenue from the transfer of goods at a point in time and of services over time in the following major product categories and geographical regions:

	For the year ended December 31, 2023		
	Domestic	International	Total
Revenue from sales of medicine	\$ 2,426,917	\$ 431,369	\$ 2,858,286
Revenue from sales of dietary supplement	126,609	–	126,609
Others	4,740	–	4,740
	<u>\$ 2,558,266</u>	<u>\$ 431,369</u>	<u>\$ 2,989,635</u>

	For the year ended December 31, 2022		
	Domestic	International	Total
Revenue from sales of medicine	\$ 2,170,984	\$ 346,257	\$ 2,517,241
Revenue from sales of dietary supplement	146,040	20	146,060
Revenue from rendering of services	1	–	1
Others	49,734	59,168	108,902
	<u>\$ 2,366,759</u>	<u>\$ 405,445</u>	<u>\$ 2,772,204</u>

B. The Company has recognised the following revenue-related contract liabilities:

	December 31, 2023	December 31, 2022	January 1, 2022
Contract liabilities – sales of medicine	<u>\$ 34,899</u>	<u>\$ 35,430</u>	<u>\$ 40,569</u>

Revenue recognised that was included in the contract liability balance at the beginning of the years ended December 31, 2023 and 2022 were \$22,762 and \$36,149, respectively.

(19) Interest income

	For the years ended December 31,	
	2023	2022
Interest income from bank deposits	<u>\$ 31,593</u>	<u>\$ 11,232</u>



(20) Other income

	For the years ended December 31,	
	2023	2022
Dividend income	\$ 10,034	\$ 9,604
Rental income	6,677	6,620
Fire insurance claim income (Note)	42,831	–
Royalty income	10,362	11,417
Technology transfer income	–	2,842
Research income	4,148	1,811
Government grants income	7,678	5,775
Other income	23,762	18,151
	<u>\$ 105,492</u>	<u>\$ 56,220</u>

(Note) Refer to Note 6 (5), 'Other Receivables'.

(21) Other gains and losses

	For the years ended December 31,	
	2023	2022
Net currency exchange gain	\$ 6,786	\$ 77,967
Net loss on disposal of property, plant and equipment	–	( 1,113)
Gain from lease modification	–	8
Net gain on financial assets at fair value through profit or loss	1,043	712
Other losses	( 216)	( 1,590)
	<u>\$ 7,613</u>	<u>\$ 75,984</u>

(22) Finance costs

	For the years ended December 31,	
	2023	2022
Interest expense		
Bank borrowings	\$ 11,105	\$ 8,262
Lease liabilities	169	197
	11,274	8,459
Less: Capitalisation of qualifying assets	( 374)	( 638)
	<u>\$ 10,900</u>	<u>\$ 7,821</u>

(23) Expenses by nature

For the year ended December 31, 2023			
	Recognised in operating costs	Recognised in operating expenses	Total
Employee benefit expenses	\$ 366,137	\$ 427,823	\$ 793,960
Depreciation on property, plant and equipment	74,415	22,133	96,548
Depreciation on right-of-use assets	813	4,541	5,354
Amortisation	4,065	3,750	7,815
	<u>\$ 445,430</u>	<u>\$ 458,247</u>	<u>\$ 903,677</u>
For the year ended December 31, 2022			
	Recognised in operating costs	Recognised in operating expenses	Total
Employee benefit expenses	\$ 324,590	\$ 398,435	\$ 723,025
Depreciation on property, plant and equipment	70,706	19,953	90,659
Depreciation on right-of-use assets	–	4,767	4,767
Amortisation	4,441	5,164	9,605
	<u>\$ 399,737</u>	<u>\$ 428,319</u>	<u>\$ 828,056</u>

(24) Employee benefit expenses

For the year ended December 31, 2023			
	Recognised in operating costs	Recognised in operating expenses	Total
Wages and salaries	\$ 305,355	\$ 360,853	\$ 666,208
Labour and health insurance expenses	30,810	29,432	60,242
Pension costs	14,626	18,804	33,430
Directors' remuneration	–	6,931	6,931
Other personnel expenses	15,346	11,803	27,149
	<u>\$ 366,137</u>	<u>\$ 427,823</u>	<u>\$ 793,960</u>
For the year ended December 31, 2022			
	Recognised in operating costs	Recognised in operating expenses	Total
Wages and salaries	\$ 277,345	\$ 342,534	\$ 619,879
Labour and health insurance expenses	19,616	28,937	48,553
Pension costs	13,451	10,145	23,596
Directors' remuneration	–	6,605	6,605
Other personnel expenses	14,178	10,214	24,392
	<u>\$ 324,590</u>	<u>\$ 398,435</u>	<u>\$ 723,025</u>

- A. The average number of employees were 810 and 805, which included 7 and 5 non-employee directors for the years ended December 31, 2023 and 2022, respectively.
- B. The average employee benefit expense were \$980 and \$896, respectively, while average wages and salaries were \$830 and \$775 for the years ended December 31, 2023 and 2022, respectively. The average wages and salaries has increased by 7% compared to prior year.
- C. The Company has set up an Audit Committee. As a result, there was no supervisors' remuneration for the years ended December 31, 2023 and 2022.
- D. Directors' remuneration were reviewed by the Compensation Committee (the Committee) based on the degree of their participation, the value contributed to the Company's operation, and the average level of the industry. Compensation for executive officers were reviewed by the Committee and resolved by the Board of Directors based on executive officers' job title, function, contribution, performance, and in consideration of the Company's future risk, etc. Employee compensation is decided based on individual's performance, contribution to the Company, performance, the market value of the position, and in consideration of the Company's future operating risk.
- E. In accordance with the Articles of Incorporation of the Company, a ratio of distributable profit of the current year (pre-tax profit before deducting employees' compensation and directors' remuneration), after covering accumulated losses, shall be distributed as employees' compensation and directors' remuneration. The ratio shall be 1%~10% for employees' compensation and shall not be higher than 3% for directors' remuneration. Employees' compensation will be distributed in the form of shares or cash. Qualification requirements of employees, including the employees of subsidiaries of the company meeting certain specific requirements, are entitled to receive aforementioned stock or cash. The Company may, by a resolution adopted by a majority vote at a meeting of board of directors attended by two-thirds of the total number of directors, have the profit distributable as employees' compensation distributed in the form of shares or in cash; and in addition thereto a report of such distribution shall be submitted to the shareholders during their meeting.
- F. Employees' compensation was accrued at \$10,108 and \$9,436 for the years ended December 31, 2023 and 2022, respectively; while directors' remuneration was accrued at \$3,150 and \$3,000 for the years ended December 31, 2023 and 2022, respectively. The aforementioned amounts recognised in salary expenses were estimated and accrued based on the distributable net profit of current year calculated based on the percentage prescribed under the Company's Articles of Incorporation. As resolved by the Board of Directors on February 27, 2024, the employees' compensation and directors' remuneration were \$10,076 and \$3,124, respectively, and the employees' compensation will be distributed in the form of cash. The employees' compensation and directors' remuneration for 2022 as resolved by the Board of Directors was \$12,417, and the employees' compensation was distributed in the form of cash. The difference between the aforementioned amount and the amount of \$12,436 recognised in the 2022 financial statements

by \$19, mainly caused by estimation differences, had been adjusted in the profit or loss for 2023. Information about employees' compensation and directors' remuneration of the Company as resolved by the Board of Directors will be posted in the "Market Observation Post System" at the website of the Taiwan Stock Exchange.

(25) Income tax

A. Income tax expense:

(a) Components of income tax expense:

	For the years ended December 31,	
	2023	2022
Current tax:		
Current tax on profits for the year	\$ 161,764	\$ 124,883
Tax on undistributed earnings	12,260	854
Over provision of prior year's income tax	( 7,876)	( 27,043)
	<u>166,148</u>	<u>98,694</u>
Deferred tax:		
Origination and reversal of temporary differences	( 6,648)	14,117
Income tax expense	<u>\$ 159,500</u>	<u>\$ 112,811</u>

(b) The income tax relating to components of other comprehensive income is as follows:

	For the years ended December 31,	
	2023	2022
Remeasurement of defined benefit obligation	<u>\$ 578</u>	<u>\$ 5,583</u>

B. Reconciliation between income tax expense and accounting profit:

	For the years ended December 31,	
	2023	2022
Tax calculated based on profit before tax and statutory tax rate	\$ 198,877	\$ 185,644
Effect of amount not allowed to be recognised under regulations	( 43,761)	( 46,644)
Tax on undistributed earnings	12,260	854
Over provision of prior year's income tax	( 7,876)	( 27,043)
Income tax expense	<u>\$ 159,500</u>	<u>\$ 112,811</u>

C. Amounts of deferred tax assets or liabilities as a result of temporary differences are as follows:

For the year ended December 31, 2023				
	January 1	Recognised in profit or loss	Recognised in other comprehensive income	December 31
Deferred tax assets				
Temporary differences:				
Bad debts	\$ 2,803	\$ 51	\$ –	\$ 2,854
Unrealised loss on inventories from market value decline	2,526	752	–	3,278
Unrealised exchange loss	–	509	–	509
Investment loss	42,498	1,092	–	43,590
Unrealised sales returns and allowance	3,953	2,402	–	6,355
Unused compensated absences	5,266	105	–	5,371
Pensions	<u>22,563</u>	<u>(1,164)</u>	<u>(578)</u>	<u>20,821</u>
	<u>\$ 79,609</u>	<u>\$ 3,747</u>	<u>(\$ 578)</u>	<u>\$ 82,778</u>
Deferred tax liabilities				
Temporary differences:				
Unrealised exchange gain	(\$ 2,901)	\$ 2,901	\$ –	\$ –
Provision for land value increment tax	<u>(61,992)</u>	<u>–</u>	<u>–</u>	<u>(61,992)</u>
	<u>(\$ 64,893)</u>	<u>\$ 2,901</u>	<u>\$ –</u>	<u>(\$ 61,992)</u>
	<u>\$ 14,716</u>	<u>\$ 6,648</u>	<u>(\$ 578)</u>	<u>\$ 20,786</u>

For the year ended December 31, 2022

			Recognised in other comprehensive	
	January 1	Recognised in profit or loss	income	December 31
Deferred tax assets				
Temporary differences:				
Bad debts	\$ 2,952	(\$ 149)	\$ -	\$ 2,803
Unrealised loss on inventories from market value decline	3,287	( 761)	-	2,526
Unrealised exchange loss	11,950	( 11,950)	-	-
Investment loss	38,815	3,683	-	42,498
Unrealised sales returns and allowance	1,565	2,388	-	3,953
Unused compensated absences	5,563	( 297)	-	5,266
Pensions	<u>32,276</u>	<u>( 4,130)</u>	<u>( 5,583)</u>	<u>22,563</u>
	<u>\$ 96,408</u>	<u>(\$ 11,216)</u>	<u>(\$ 5,583)</u>	<u>\$ 79,609</u>
Deferred tax liabilities				
Temporary differences:				
Unrealised exchange gain	\$ -	(\$ 2,901)	\$ -	(\$ 2,901)
Provision for land value increment tax	( 61,992)	-	-	( 61,992)
	<u>(\$ 61,992)</u>	<u>(\$ 2,901)</u>	<u>\$ -</u>	<u>(\$ 64,893)</u>
	<u>\$ 34,416</u>	<u>(\$ 14,117)</u>	<u>(\$ 5,583)</u>	<u>\$ 14,716</u>

D. The Company's income tax returns through 2021 have been assessed and approved by the Tax Authority. The Company does not have any administrative remedy as of February 27, 2024.

(26) Earnings per share

For the year ended December 31, 2023			
	<u>Amount after tax</u>	<u>Weighted average number of ordinary shares outstanding (shares in thousands)</u>	<u>Earnings per share (in dollars)</u>
<u>Basic earnings per share</u>			
Profit attributable to ordinary shareholders	<u>\$ 834,886</u>	<u>178,696</u>	<u>\$ 4.67</u>
<u>Diluted earnings per share</u>			
Profit attributable to ordinary shareholders	\$ 834,886	178,696	
Assumed conversion of all dilutive potential ordinary shares Employees' compensation	<u>—</u>	<u>194</u>	
Profit attributable to ordinary shareholders plus assumed conversion of all dilutive potential ordinary shares	<u>\$ 834,886</u>	<u>178,890</u>	<u>\$ 4.67</u>

For the year ended December 31, 2022			
	<u>Amount after tax</u>	<u>Weighted average number of ordinary shares outstanding (shares in thousands)</u>	<u>Earnings per share (in dollars)</u>
<u>Basic earnings per share</u>			
Profit attributable to ordinary shareholders	<u>\$ 815,408</u>	<u>178,696</u>	<u>\$ 4.56</u>
<u>Diluted earnings per share</u>			
Profit attributable to ordinary shareholders	\$ 815,408	178,696	
Assumed conversion of all dilutive potential ordinary shares Employees' compensation	<u>—</u>	<u>189</u>	
Profit attributable to ordinary shareholders plus assumed conversion of all dilutive potential ordinary shares	<u>\$ 815,408</u>	<u>178,885</u>	<u>\$ 4.56</u>

(27) Transactions with non-controlling interest

- A. In September 2022, the Company acquired part of shares of its subsidiary—Souriree Biotech Pharmaceutical Co., Ltd. for a total cash consideration of \$322. The carrying amount was \$305 at the acquisition date. This transaction resulted in a decrease in the equity attributable to the Company by \$17.
- B. Refer to Note 6(7), ‘Investments accounted for under equity method’, and Note 6(15), ‘Capital surplus’ for more information regarding the effect on the Company of the spin off and transfer of the synthesis department to the subsidiary, Syn-Tech Chem. & Pharm. Co., Ltd. in July 2022.
- C. There was no such transaction for the year ended December 31, 2023.

(28) Supplemental cash flow information

- A. Investing activities with partial cash payments:

	For the years ended December 31,	
	2023	2022
(1) Acquisition of property, plant and equipment	\$ 55,130	\$ 171,793
Add: Beginning balance of notes payable	5,141	3,010
Beginning balance of payable on equipment (listed as “Other payables”)	16,328	7,027
Less: Ending balance of notes payable	( 1,617)	( 5,141)
Ending balance of payable on equipment (listed as “Other payables”)	( 5,548)	( 16,328)
Capitalised interest	( 374)	( 638)
Cash paid for acquisition of property, plant and equipment	<u>\$ 69,060</u>	<u>\$ 159,723</u>
(2) Acquisition of investments accounted for under equity method	\$ 5,578	\$ 260,190
Less: Transferred from prepaid shares	( 5,578)	–
Shares acquired from spin-off (Note)	–	( 208,627)
Cash paid for acquisition of investments accounted for under equity method	<u>\$ –</u>	<u>\$ 51,563</u>
(3) Proceeds from disposal of other non-current assets	\$ –	\$ –
Add: Beginning balance of other receivables	–	38,364
Less: Ending balance of other receivables	–	–
Cash received from disposal of other non-current assets	<u>\$ –</u>	<u>\$ 38,364</u>

(Note) Refer to Note 6 (7), ‘Investments accounted for under equity method’.



B. Operating and investing activities with no cash flow effects:

	For the years ended December 31,	
	2023	2022
(1) Prepayments for equipment transferred to property, plant and equipment	\$ 35,115	\$ 94,299
(2) Property, plant and equipment transferred to expenses	\$ 2,134	\$ -
(3) Property, plant and equipment transferred to Investment property, net	\$ -	\$ 16,995

(29) Changes in liabilities from financing activities

	Short-term borrowings	Lease liabilities	Guarantee deposits received	Total
At January 1, 2023	\$ 870,000	\$ 15,984	\$ 200	\$ 886,184
Changes in cash flow from financing activities	( 410,000)	( 5,390)	8,533	( 406,857)
Changes in other non-cash items	-	2,619	-	2,619
At December 31, 2023	\$ 460,000	\$ 13,213	\$ 8,733	\$ 481,946

	Short-term borrowings	Lease liabilities	Guarantee deposits received	Total
At January 1, 2022	\$ 710,500	\$ 18,109	\$ 235	\$ 728,844
Changes in cash flow from financing activities	159,500	( 4,842)	( 35)	154,623
Changes in other non-cash items	-	2,717	-	2,717
At December 31, 2022	\$ 870,000	\$ 15,984	\$ 200	\$ 886,184

## 7. RELATED PARTY TRANSACTIONS

### (1) Names of related parties and relationship

<u>Names of related parties</u>	<u>Relationship with the Company</u>
Standard Pharmaceutical Co., Ltd. (Standard P)	Subsidiary
Chia Scheng International Co., Ltd. (Chia Scheng)(Note)	Subsidiary
Standard Chem. & Pharm. Philippines, Inc. (PHL)	Subsidiary
Inforight Technology Co., Ltd. (Inforight)	Subsidiary
Souriree Biotech & Pharm. Co., Ltd. (Souriree)	Subsidiary
Multipower Enterprise Corp. (Multipower)	Subsidiary
Advpharma Inc. (Adv)	Subsidiary
Syngen Biotech Co., Ltd. (Syngen)	Subsidiary
Jiangsu Standard Biotech Pharmaceutical Co., Ltd. (Jiangsu Standard)	Subsidiary
Syn-Tech Chem. & Pharm. Co., Ltd. (Syn-Tech)	Subsidiary
Zhanshuo Biotech & Pharm. Co., Ltd. (Zhanshuo)	Subsidiary
Ho Yao Biopharm Co., LTD.(Ho Yao)	Subsidiary
Shanghai Standard Pharmaceutical Co., Ltd. (Shanghai Standard)	Subsidiary
We Can Medicines Co., Ltd. (We Can)	Associate
Taiwan Biosim Co., Ltd. (Biosim)	Associate
Sun You Biotech Pharm Co., Ltd. (Sun You)	Other related party (The manager of the Company is Sun You's director)
Fan Dao Nan Foundation (Fan Dao Nan)	Other related party (The corporate director of the Company)

(Note) Formerly named as 'Chia Scheng Investment Co., Ltd.' and the name was changed since October 12, 2023.

### (2) Significant related party transactions

#### A. Sales of goods

	<u>For the years ended December 31,</u>	
	<u>2023</u>	<u>2022</u>
Subsidiaries	\$ 8,658	\$ 6,464
Associates	12,005	10,604
Other related parties	20,582	23,342
	<u>\$ 41,245</u>	<u>\$ 40,410</u>

Prices of goods sold to related parties are determined each time when delivering goods. The payment term of the subsidiaries is to obtain cheques due in 3~4 months. For other related parties, terms of transactions are similar with those to third parties, which is cash payment in 2 months after billing, or to obtain cheques with a maturity of 4~6 months upon billing.

B. Purchases of goods

	For the years ended December 31,	
	2023	2022
Subsidiaries	\$ 167,485	\$ 188,898
Associates	–	2,475
Other related parties	5,284	4,471
	<u>\$ 172,769</u>	<u>\$ 195,844</u>

Goods are purchased based on the price lists in force and terms that would be available to regular suppliers. Payment terms are 1 ~ 4 months after monthly billings.

C. Property transactions

(a) Acquisition of property, plant and equipment:

	2023	2022
Subsidiaries	\$ 2,070	\$ –

(b) Disposal of property, plant and equipment:

	For the year ended December 31, 2022	
	Proceeds from	Gain on disposal
Other related parties	\$ 6	\$ 6

There was no such transaction for the year ended December 31, 2023.

D. Equity transactions

The Company spin off and transferred the synthesis department to Syn-Tech and received the common shares issued from the capital increase with total value of \$208,627 in July 2022. There was no such transaction for the year ended December 31, 2023.

E. Other expenses

	For the years ended December 31,	
	2023	2022
Advertisement expenses:		
Subsidiaries	\$ 1,081	\$ 193
Associates	42	58
	<u>\$ 1,123</u>	<u>\$ 251</u>

		For the years ended December 31,	
		2023	2022
Research and development expenses:			
Subsidiaries		\$ 31,052	\$ 12,862
Professional service fees:			
Subsidiaries		\$ 3,964	\$ 3,208
Miscellaneous expenses:			
Subsidiaries		\$ 810	\$ 1,412
Associates		146	1,172
Other related parties		–	49
		<u>\$ 956</u>	<u>\$ 2,633</u>

F. Rental income

		For the years ended December 31,	
		2023	2022
	Leased assets		
Subsidiaries	Land, Buildings and other equipments		
	Rent collection		
	Monthly	\$ 6,192	\$ 6,144

G. Other income

		For the years ended December 31,	
		2023	2022
Subsidiaries		\$ 11,442	\$ 9,803
Associates		300	68
Other related parties		35	2,292
		<u>\$ 11,777</u>	<u>\$ 12,163</u>

H. Ending balance of goods sold

		December 31, 2023	December 31, 2022
Receivables from related parties:			
Subsidiaries		\$ 2,484	\$ 3,513
Associates		2,576	1,679
Other related parties		6,858	7,706
		<u>\$ 11,918</u>	<u>\$ 12,898</u>

The receivables from related parties arise mainly from sales transactions. The receivables are unsecured in nature and bear no interest. There are no provisions held against receivables from related parties.

I. Other receivables

	December 31, 2023	December 31, 2022
Subsidiaries	\$ 470	\$ 1,885
Associates	3,744	–
Other related parties	–	1,180
	<u>\$ 4,214</u>	<u>\$ 3,065</u>

J. Ending balance of goods purchased

	December 31, 2023	December 31, 2022
Payables to related parties:		
Subsidiaries	\$ 42,821	\$ 40,085
Other related parties	2,268	1,626
	<u>\$ 45,089</u>	<u>\$ 41,711</u>

The payables to related parties arise mainly from purchase transactions. The payables bear no interest.

K. Lease transactions — lessee

- (a) The Company leases land from other related party, Fan Dao Nan. Rental contracts are made for the period from October 1, 2016 to September 30, 2027. Rents are paid quarterly.
- (b) As of December 31, 2023 and 2022, the carrying amount of right-of-use assets were \$2,249 and \$2,848, respectively.
- (c) As of December 31, 2023 and 2022, the carrying amount of lease liability were \$2,315 and \$2,915, respectively. The Company recognised interest expenses amounting to \$30 and \$37 for the years ended December 31, 2023 and 2022, respectively (listed as ‘Finance costs’).

(3) Key management compensation

	For the years ended December 31,	
	2023	2022
Salaries and other short-term employee benefits	<u>\$ 18,288</u>	<u>\$ 15,765</u>

8. PLEDGED ASSETS

None.

9. SIGNIFICANT CONTINGENT LIABILITIES AND UNRECOGNISED CONTRACT COMMITMENTS

The balances for contracts that the Company entered into for the purchase of property, plant and equipment, but not yet due were \$34,659 and \$20,320 as of December 31, 2023 and 2022, respectively.

10. SIGNIFICANT DISASTER LOSS

None.

11. SIGNIFICANT EVENT AFTER THE BALANCE SHEET DATE

None.

## 12. OTHERS

### (1) Capital management

The Company's objectives when managing capital are to safeguard the Company's ability to continue as a going concern in order to provide returns for shareholders and to maintain an optimal capital structure to reduce the cost of capital. In order to maintain or adjust the capital structure, the Company may adjust the amount of dividends paid to shareholders, return capital to shareholders, issue new shares or sell assets to reduce debt.

### (2) Financial instruments

#### A. Financial instruments by category

	<u>December 31, 2023</u>	<u>December 31, 2022</u>
<u>Financial assets</u>		
Financial assets at fair value through profit or loss		
Financial assets mandatorily measured at fair value through profit or loss	\$ <u>11,604</u>	\$ <u>10,561</u>
Financial assets at fair value through other comprehensive income		
Designation of equity instruments	\$ <u>343,837</u>	\$ <u>248,366</u>
Financial assets at amortised cost		
Cash and cash equivalents	\$ 715,774	\$ 858,252
Financial assets at amortised cost	8,000	–
Notes receivable	109,055	100,411
Accounts receivable	578,405	533,695
Other receivables	11,314	72,290
Guarantee deposits paid	<u>38,291</u>	<u>25,685</u>
	<u>\$ 1,460,839</u>	<u>\$ 1,590,333</u>
<u>Financial liabilities</u>		
Financial liabilities at amortised cost		
Short-term borrowings	\$ 460,000	\$ 870,000
Notes payable	134,316	141,490
Accounts payable	166,760	142,739
Other payables	252,697	248,593
Guarantee deposits received	<u>8,733</u>	<u>200</u>
	<u>\$ 1,022,506</u>	<u>\$ 1,403,022</u>
Lease liabilities	<u>\$ 13,213</u>	<u>\$ 15,984</u>

#### B. Risk management policies

(a) The Company's activities expose it to a variety of financial risks: market risk (including foreign exchange risk, price risk and interest rate risk), credit risk and liquidity risk. To minimise any adverse effects on the financial performance of the Company, derivative financial instruments may be used to hedge certain risk.

(b) Risk management is carried out by a central treasury department (Company treasury) under

policies approved by the Board of Directors. Company treasury identifies, evaluates and hedges financial risks in close cooperation with the Company's operating units. The Board provides written principles for overall risk management, as well as written policies covering specific areas and matters, such as foreign exchange risk, interest rate risk, credit risk, use of derivative financial instruments and non-derivative financial instruments.

C. Significant financial risks and degrees of financial risks

(a) Market risk

Foreign exchange risk

- i. The Company operates internationally and is exposed to foreign exchange risk arising from the transactions of the Company used in various functional currency, primarily with respect to the USD, JPY and RMB. Foreign exchange risk arises from future commercial transactions and recognised assets and liabilities.
- ii. The Company has certain sales and purchases denominated in USD and other foreign currencies. Changes in market exchange rates would affect the fair value. However, the payment and collection periods of asset and liability positions in foreign currencies are close, market risk can be offset. The Company does not expect significant interest rate risk.
- iii. The Company has certain investments in foreign operations, whose net assets are exposed to foreign currency translation risk. However, the net investments of foreign operations are strategic investments, thus the Company does not hedge the investments.
- iv. The Company's businesses involve some non-functional currency operations (the Company's functional currency: NTD). The information on assets and liabilities denominated in foreign currencies whose values would be materially affected by the exchange rate fluctuations is as follows:

December 31, 2023			
(Foreign currency: functional currency)	Foreign currency		
	amount		
	(In thousands)	Exchange rate	Book value
<u>Financial assets</u>			
<u>Monetary items</u>			
USD: NTD	\$ 23,025	30.71	\$ 707,084
JPY: NTD	65,834	0.2172	14,299
RMB: NTD	3,509	4.327	15,185
<u>Investments accounted for under equity method</u>			
USD: NTD	5,838	30.71	179,272
RMB: NTD	297	4.327	1,285
PHP: NTD	7,206	0.5545	3,996
<u>Financial liabilities</u>			
<u>Monetary items</u>			
USD: NTD	113	30.71	3,469

December 31, 2022			
(Foreign currency: functional currency)	Foreign currency		
	amount		
	(In thousands)	Exchange rate	Book value
<u>Financial assets</u>			
<u>Monetary items</u>			
USD: NTD	\$ 29,020	30.71	\$ 891,196
JPY: NTD	163,316	0.2324	37,955
RMB: NTD	4,086	4.408	18,010
<u>Investments accounted for under equity method</u>			
USD: NTD	5,918	30.71	181,720
RMB: NTD	743	4.408	3,274
PHP: NTD	576	0.5443	314
<u>Financial liabilities</u>			
<u>Monetary items</u>			
USD: NTD	302	30.71	9,285

With regard to sensitivity analysis of foreign currency exchange rate risk, if the exchange rates of NTD to all foreign currencies had appreciated/depreciated by 1%, with all other



factors remaining constant, the Company's net income for the years ended December 31, 2023 and 2022 would have increased/decreased by \$ 5,865 and \$ 7,505, respectively.

- v. Total exchange income, including realised and unrealised, arising from significant foreign exchange variation on the monetary items held by the Company for the years ended December 31, 2023 and 2022 amounted to \$ 6,786 and \$77,967, respectively.

#### Price risk

- i. The Company's equity securities, which are exposed to price risk, are the held financial assets at fair value through profit or loss and financial assets at fair value through other comprehensive income. To manage its price risk arising from investments in equity securities, the Company diversifies its portfolio. Diversification of the portfolio is done in accordance with the limits set by the Company.
- ii. The Company's investments in equity securities comprise shares issued by the domestic companies. The prices of equity securities would change due to the change of the future value of investee companies. If the prices of these equity securities had increased/decreased by 1% with all other variables held constant, post-tax profit for the years ended December 31, 2023 and 2022 would have both increased/decreased by \$249, as a result of gains/losses on equity securities classified as at fair value through profit or loss. Other components of equity would have increased/decreased by \$1,928 and \$2,273, respectively, as a result of other comprehensive income classified as equity investment at fair value through other comprehensive income.

#### Cash flow and fair value interest rate risk

- i. The Company's main interest rate risk arises from short-term borrowings with variable rates, which expose the Company to cash flow interest rate risk. During the years ended December 31, 2023 and 2022, the Company's borrowings at variable rate were denominated in the NTD.
- ii. With regard to sensitivity analysis of interest rate risk, if interest rates on borrowings at that date had been 1% higher/lower with all other variables held constant, post-tax profit for the years ended December 31, 2023 and 2022 would have been \$86 and \$61 lower/higher, respectively, mainly as a result of higher/lower interest expense on floating rate borrowings.

#### (b) Credit risk

- i. Credit risk refers to the risk of financial loss to the Company arising from default by the clients or counterparties of financial instruments on the contract obligations. The main factor is that counterparties could not repay in full the accounts receivable based on the agreed terms.
- ii. The Company manages its credit risk taking into consideration the entire company's concern. According to the Company's credit policy, the Company is responsible for managing and analysing the credit risk for each of their new clients before standard payment and delivery terms and conditions are offered. Internal risk control assesses the

credit quality of the customers, taking into account their financial position, past experience and other factors. Individual risk limits are set based on internal or external ratings in accordance with limits set by the Board of Directors. The utilisation of credit limits is regularly monitored.

- iii. In line with credit risk management procedure, payment reminders are sent as the contract payments are past due, whereby the default occurs when the contract payments are past due over certain period of time, and recourse procedures are initiated. However, the Company will continue executing the recourse procedures to secure their rights.
- iv. The Company classifies customer's notes and accounts receivable in accordance with credit rating of customer. The Company applies the modified approach using provision matrix to estimate expected credit loss under the provision matrix basis. The Company used the forecastability of conditions to adjust historical and timely information to assess the default possibility of notes and accounts receivable, whereby rate ranging from 0.01% to 100% are applied to the provision matrix. Movements in relation to the Company applying the modified approach to provide loss allowance for notes and accounts receivable are as follows:

	For the year ended December 31, 2023		
	Notes receivable	Accounts receivable	Total
Beginning balance	\$ –	\$ 4, 256	\$ 4, 256
Provision for impairment	–	281	281
Ending balance	<u>\$ –</u>	<u>\$ 4, 537</u>	<u>\$ 4, 537</u>
	For the year ended December 31, 2022		
	Notes receivable	Accounts receivable	Total
Beginning balance	\$ –	\$ 5, 093	\$ 5, 093
Reversal of impairment	–	( 837)	( 837)
Ending balance	<u>\$ –</u>	<u>\$ 4, 256</u>	<u>\$ 4, 256</u>

(c) Liquidity risk

- i. Cash flow forecasting is performed in the operating entities of the Company and aggregated by Company treasury. Company treasury monitors rolling forecasts of the Company's liquidity requirements to ensure it has sufficient cash to meet operational needs while maintaining sufficient headroom on its undrawn committed borrowing facilities at all times so that the Company does not breach borrowing limits or covenants on any of its borrowing facilities.
- ii. Surplus cash held by the Company over and above balance required for working capital management are transferred to the Company treasury. Company treasury invests surplus cash in interest bearing current accounts, time deposits and marketable securities, choosing instruments with appropriate maturities or sufficient liquidity to provide sufficient headroom as determined by the abovementioned forecasts.

iii. The Company has the following undrawn borrowing facilities:

	<u>December 31, 2023</u>	<u>December 31, 2022</u>
Floating rate:		
Expiring within one year	<u>\$ 1,754,970</u>	<u>\$ 1,264,970</u>

iv. The table below analyses the Company's non-derivative financial liabilities into relevant maturity groupings based on the remaining period at the balance sheet date to the contractual maturity date:

<u>December 31, 2023</u>	<u>Within 1 year</u>	<u>Between 1 and 2 years</u>	<u>Between 2 and 5 years</u>	<u>Over 5 years</u>
Short-term borrowings	\$ 461,079	\$ –	\$ –	\$ –
Notes payable	134,316	–	–	–
Accounts payable	166,760	–	–	–
Other payables	252,697	–	–	–
Lease liabilities	5,410	4,603	3,398	–
Guarantee deposits received	3	–	8,730	–

<u>December 31, 2022</u>	<u>Within 1 year</u>	<u>Between 1 and 2 years</u>	<u>Between 2 and 5 years</u>	<u>Over 5 years</u>
Short-term borrowings	\$ 872,774	\$ –	\$ –	\$ –
Notes payable	141,490	–	–	–
Accounts payable	142,739	–	–	–
Other payables	248,593	–	–	–
Lease liabilities	4,595	4,523	7,191	–
Guarantee deposits received	–	200	–	–

v. For non-derivative financial liabilities, the Company does not expect the timing of occurrence of the cash flows estimated through the maturity date analysis will be significantly earlier, nor expect the actual cash flow amount will be significantly different.

### (3) Fair value information

A. The different levels that the inputs to valuation techniques are used to measure fair value of financial and non-financial instruments have been defined as follows:

Level 1: Quoted prices (unadjusted) in active markets for identical assets or liabilities that the entity can access at the measurement date. A market is regarded as active where a market in which transactions for the asset or liability take place with sufficient frequency and volume to provide pricing information on an ongoing basis. The fair value of the Company's investment in listed stocks is included.

Level 2: Inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly.

Level 3: Unobservable inputs for the asset or liability. The Company's investment in partial equity instruments without active market is included.

B. The carrying amounts of the Company's financial instruments not measured at fair value (including cash and cash equivalents, financial assets at amortised cost, notes receivable, accounts receivable, other receivables, guarantee deposits paid, short-term borrowings, notes payable, accounts payable, other payables, and guarantee deposits received) are approximate to their fair values.

C. The related information on financial and non-financial instruments measured at fair value by level on the basis of the nature, characteristics and risks of the assets is as follows:

(a) The related information on the nature of the assets is as follows:

December 31, 2023	Level 1	Level 2	Level 3	Total
<u>Recurring fair value measurements</u>				
Financial assets at fair value through profit or loss				
Equity securities	\$ -	\$ -	\$ 11,604	\$ 11,604
Financial assets at fair value through other comprehensive income				
Equity securities	243,007	-	100,830	343,837
	<u>\$ 243,007</u>	<u>\$ -</u>	<u>\$ 112,434</u>	<u>\$ 355,441</u>
December 31, 2022	Level 1	Level 2	Level 3	Total
<u>Recurring fair value measurements</u>				
Financial assets at fair value through profit or loss				
Equity securities	\$ -	\$ -	\$ 10,561	\$ 10,561
Financial assets at fair value through other comprehensive income				
Equity securities	154,874	-	93,492	248,366
	<u>\$ 154,874</u>	<u>\$ -</u>	<u>\$ 104,053</u>	<u>\$ 258,927</u>

(b) The methods and assumptions the Company used to measure fair value are as follows:

i. The instruments that the Company used market quoted prices as their fair values (that is, Level 1) are listed below by characteristics:

	<u>Listed stocks</u>
Market quoted price	Closing price

ii. Except for financial instruments with active markets, the fair value of other financial instruments is measured by using valuation techniques or by reference to counterparty quotes. The fair value of financial instruments measured by using valuation techniques

can be referred to current fair value of instruments with similar terms and characteristics in substance, discounted cash flow method or other valuation methods, including calculated by applying model using market information available at the parent company only balance sheet date.

- iii. The output of valuation model is an estimated value and the valuation technique may not be able to capture all relevant factors of the Company's financial and non-financial instruments. Therefore, the estimated value derived using valuation model is adjusted accordingly with additional inputs, for example, model risk or liquidity risk and etc. In accordance with the Company's management policies and relevant control procedures relating to the valuation models used for fair value measurement, management believes adjustment to valuation is necessary in order to reasonably represent the fair value of financial and non-financial instruments in the parent company only balance sheet. The inputs and pricing information used during valuation are carefully assessed and adjusted based on current market conditions.

D. There was no transfer between Level 1 and Level 2 in 2023 and 2022.

E. The following table presents the changes in Level 3 instruments in 2023 and 2022:

	For the years ended December 31,	
	2023	2022
At January 1	\$ 104, 053	\$ 100, 434
Recognised in profit or loss (Note 1)	1, 043	712
Recognised in other comprehensive income (Note 2)	7, 338	2, 907
At December 31	<u>\$ 112, 434</u>	<u>\$ 104, 053</u>

(Note 1) Listed as "Other gains and losses".

(Note 2) Listed as "Unrealised gain or loss on financial assets at fair value through other comprehensive income".

F. For the years ended December 31, 2023 and 2022, there was no transfer from or to Level 3.

G. Financial segment is in charge of valuation procedures for fair value measurements being categorised within Level 3, which is to verify independent fair value of financial instruments. Such assessment is to ensure the valuation results are reasonable by applying independent information to make results close to current market conditions, confirming the resource of information is independent, reliable and in line with other resources and represented as the exercisable price, and frequently calibrating valuation model, performing back-testing, updating inputs used to the valuation model and making any other necessary adjustments to the fair value.

H. The following is the qualitative information of significant unobservable inputs and sensitivity analysis of changes in significant unobservable inputs to valuation model used in Level 3 fair value measurement.

		<u>Fair value at December 31, 2023</u>	<u>Valuation technique</u>	<u>Significant unobservable input</u>	<u>Range (weighted average)</u>	<u>Relationship of inputs to fair value</u>
Non-derivative equity instrument:						
Unlisted stocks	\$	112,434	Market comparable companies	Discount for lack of marketability	30%	The higher the discount for lack of marketability, the lower the fair value
		<u>Fair value at December 31, 2022</u>	<u>Valuation technique</u>	<u>Significant unobservable input</u>	<u>Range (weighted average)</u>	<u>Relationship of inputs to fair value</u>
Non-derivative equity instrument:						
Unlisted stocks	\$	104,053	Market comparable companies	Discount for lack of marketability	30%	The higher the discount for lack of marketability, the lower the fair value

I. The Company has carefully assessed the valuation models and assumptions used to measure fair value; therefore, the fair value measurement is reasonable. However, use of different valuation models or assumptions may result in different measurement. The following is the effect on profit or loss or on other comprehensive income from financial assets categorised within Level 3 if the inputs used to valuation models have changed:

			<u>December 31, 2023</u>			
			<u>Recognised in profit or loss</u>		<u>Recognised in other comprehensive income</u>	
			<u>Favourable change</u>	<u>Unfavourable change</u>	<u>Favourable change</u>	<u>Unfavourable change</u>
	<u>Input</u>	<u>Change</u>				
Financial assets						
Equity instrument	Discount for lack of	± 3%	<u>\$ 497</u>	<u>(\$ 497)</u>	<u>\$ 4,321</u>	<u>(\$ 4,321)</u>
			<u>December 31, 2022</u>			
			<u>Recognised in profit or loss</u>		<u>Recognised in other comprehensive income</u>	
			<u>Favourable change</u>	<u>Unfavourable change</u>	<u>Favourable change</u>	<u>Unfavourable change</u>
	<u>Input</u>	<u>Change</u>				
Financial assets						
Equity instrument	Discount for lack of	± 3%	<u>\$ 453</u>	<u>(\$ 453)</u>	<u>\$ 4,007</u>	<u>(\$ 4,007)</u>

### 13. SUPPLEMENTARY DISCLOSURES

(Only 2023 information is disclosed in accordance with the current regulatory requirements.)

#### (1) Significant transactions information

- A. Loans to others: Refer to table 1.
- B. Provision of endorsements and guarantees to others: None.
- C. Holding of marketable securities at the end of the year (not including subsidiaries, associates and joint ventures): Refer to table 2.
- D. Acquisition or sale of the same security with the accumulated cost exceeding \$300 million or 20% of the Company's paid-in capital or more: None.
- E. Acquisition of real estate reaching \$300 million or 20% of paid-in capital or more: None.
- F. Disposal of real estate reaching \$300 million or 20% of paid-in capital or more: None.
- G. Purchases or sales of goods from or to related parties reaching \$100 million or 20% of paid-in capital or more: None.
- H. Receivables from related parties reaching \$100 million or 20% of paid-in capital or more: None.
- I. Trading in derivative instruments undertaken during the reporting periods: None.
- J. Significant inter-company transactions during the reporting periods: Refer to table 3.

#### (2) Information on investees

Names, locations and other information of investee companies (not including investees in Mainland China): Refer to table 4.

#### (3) Information on investments in Mainland China

- A. Basic information: Refer to table 5.
- B. Significant transactions, either directly or indirectly through a third area, with investee companies in the Mainland Area: None.

#### (4) Main stockholders information

Main stockholders information: Refer to table 6.

### 14. SEGMENT INFORMATION

Not applicable.

STANDARD CHEM & PHARM. CO., LTD.

Loans to others

For the year ended December 31, 2023

Table 1

Expressed in thousands of NTD

Number	Creditor	Borrower	General ledger account	Is a related party	Maximum outstanding balance	Ending balance (Note 2)	Actual amount drawn down	Interest rate	Nature of loan (Note 1)	Amount of transactions with the borrower	Reason for short-term financing	Allowance for doubtful accounts	Collateral		Limit on loans granted to a single party	Ceiling on total loans granted	Note
													Item	Value			
1	Standard Pharmaceutical Co., Ltd.	Jiangsu Standard Biotech Pharmaceutical Co., Ltd.	Other receivables	Yes	\$ 92,130	\$ 92,130	\$ 92,130	1.20%	2	-	Operating capital	-	—	-	\$ 376,757	\$ 376,757	(Notes 3)
2	Jiangsu Standard Biotech Pharmaceutical Co., Ltd.	Jiangsu Standard-Dia Biopharma Co., Ltd.	Other receivables	Yes	4,543	4,543	4,543	1.20%	2	-	Operating capital	-	—	-	12,035	14,442	(Notes 3)

Note 1: The code represents the nature of financing activities as follows:

- (1) Trading partner.
- (2) Short-term financing.

Note 2: The ending balance is the credit limit approved by the Board of Directors.

Note 3: Calculation of limit on loans granted to a single party and ceiling on total loans granted:

- (1) Limit on loans granted to a single party:
  - (a) For the companies having business relationship with the Company, limit on loans granted to a single party is the higher value of purchasing and selling during current or latest year on the year of financing.
  - (b) For short-term financing, limit on loans granted to a single party is 5% of the Company's net assets based on the latest audited consolidated financial statements.
  - (c) Limit on loans granted by Standard Pharmaceutical Co., Ltd. to a single party is 200% of the creditor's net assets based on the latest audited or reviewed consolidated financial statements.
  - (d) Limit on loans granted by Jiangsu Standard Biotech Pharmaceutical to a single party is 25% of the creditor's net assets based on the latest audited or reviewed consolidated financial statements.
- (2) Ceiling on total loans granted to a single party:
  - (a) Ceiling on total loans granted by Standard Pharmaceutical Co., Ltd. to single party is 200% of the creditor's net assets.
  - (b) Ceiling on total loans granted by Jiangsu Standard Biotech Pharmaceutical to single party is 30% of the creditor's net assets.
- (3) For short-term financing, ceiling on total loans granted to all direct or indirect wholly-owned domestic and foreign subsidiaries of the Company is not limited to 40% of the creditors' net assets.

Note 4: Foreign currencies were translated into New Taiwan Dollars with exchange rate as of December 31, 2023 as follows: USD: NTD 1:30.71 and RMB: NTD 1:4.327.



STANDARD CHEM & PHARM. CO., LTD.

Holding of marketable securities at the end of the period (not including subsidiaries, associates and joint ventures)

December 31, 2023

Table 2

Expressed in thousands of NTD

Securities held by	Marketable securities	Relationship with the securities issuer	General ledger account	Number of shares	As of December 31, 2023			Note
					Book value	Ownership (%)	Fair value	
Standard Chem & Pharm. Co., Ltd.	Bonds with repurchase agreement:							
	China Bills Finance Corporation	—	1	—	\$ 18,424	-	\$ 18,424	-
	Stocks:							
	Original BioMedicals Co., Ltd.	—	2	200,000	-	0.43%	-	-
	NCKU Venture Capital Co., Ltd.	—	3	650,000	3,913	4.17%	3,913	-
	NTU Innovation & Incubation Co., Ltd.	—	3	480,000	3,883	3.76%	3,883	-
	TaiwanJ Pharmaceuticals Co., Ltd.	—	3	258,133	3,808	0.34%	3,808	-
	HER-SING CO., LTD.	The Company is HER-SING Co., Ltd.'s corporate director	4	3,055,000	48,819	17.71%	48,819	-
	SUN YOU BIOTECH PHARM CO., LTD.		4	3,378,006	45,738	18.13%	45,738	-
	Green Management International Co., Ltd.	—	4	109,672	1,873	5.14%	1,873	-
	Kenda Pharmaceutiocal Co., Ltd.	—	4	5,000,000	4,400	19.42%	4,400	-
Chia Scheng International Co., Ltd.	Rossmax International Ltd.	—	4	1,304,000	32,600	1.54%	32,600	-
	EASYWELL BIOMEDICALS, INC.	—	4	5,094,600	210,407	4.45%	210,407	-
	Beneficiary certificates:							
	Taishin Ta-Chong Money Market Fund	—	2	368,142	5,378	-	5,378	-
	Taishin 1699 Money Market Fund	—	2	50,000	697	-	697	-
	Stocks:							
	SUN YOU BIOTECH PHARM CO., LTD.	The manager of the Company is SUN YOU BIOTECH PHARM CO., LTD.'s director	4	240,846	3,261	1.29%	3,261	-
MULTIPOWER ENTERPRISE CORP.	Stason Pharmaceuticals, Inc.	—	4	4,000,000	-	13.02%	-	-
	Bonds with repurchase agreement:							
	International Bills Finance Corporation	—	1	—	80,000	-	80,000	-
	Mega Bills Finance Co., Ltd.	—	1	—	20,000	-	20,000	-
Advpharma Inc.	Beneficiary certificates:							
	Mega Diamond Money Market Fund	—	2	3,166,588	40,846	-	40,846	-
	FSITC Taiwan Money Market Fund	—	2	1,652,490	26,007	-	26,007	-
	Taishin 1699 Money Market Fund	—	2	1,473,047	20,538	-	20,538	-
	UPAMC James Bond Money Market Fund	—	2	1,662,198	28,501	-	28,501	-
	Shin Kong US Harvest Balanced USD A	—	2	245,916	2,693	-	2,693	-
	Cathay Senior Secured High Yield Bond	—	2	368,302	4,044	-	4,044	-
	Capital Money Market Fund	—	2	1,658,329	27,507	-	27,507	-
	Shin Kong Emergin Wealthy Nations Bond Fund A	—	2	195,290	1,778	-	1,778	-

Securities held by	Marketable securities	Relationship with the securities issuer	General ledger account	Number of shares	As of December 31, 2023			
					Book value	Ownership (%)	Fair value	Note
Advpharma Inc.	Fubon NASDAQ-100 Index ETF	—	2	2,000	\$ 134	-	\$ 134	-
	Yuanta Taiwan High Dividend Low Volatility ETF	—	2	2,000	101	-	101	-
	CTBC Taiwan ESG Leading Semiconductor ETF	—	2	3,000	49	-	49	-
	CTBC TIP Customized Taiwan Green Energy and Electric Vehicles ETF	—	2	1,000	16	-	16	-
	SinoPac Taiwan Superior Dividend Highlight Stocks ETF	—	2	2,000	30	-	30	-
	KGI Taiwan Premium Selection High Dividend 30 ETF	—	2	3,000	67	-	67	-
	Capital Tip Customized Taiwan Select High Dividend ETF	—	2	2,000	45	-	45	-
	Cathay Taiwan Leaders 50 ETF	—	2	3,000	51	-	51	-
	Fuh Hwa Taiwan Technology Dividend Highlight ETF	—	2	4,000	77	-	77	-
	Yuanta US 20+ Year BBB Corporate Bond ETF	—	2	1,000	36	-	36	-
	CAPITAL ICE ESG 20+ Year BBB Us Corporate ETF	—	2	1,000	16	-	16	-
	Stocks:							
	Taiwan Cement Corporation	—	2	2,000	70	-	70	-
	Universal Cement Corporation	—	2	1,000	30	-	30	-
	CHAROEN POKPHAND ENTERPRISE(TAIWAN) CO., LTD.	—	2	4,000	384	-	384	-
Advpharma Inc.	Cathay Consolidated,INC.	—	2	1,000	120	-	120	-
	Tainan Enterprises Co., Ltd.	—	2	5,000	146	-	146	-
	CHUNG-HSIN ELECTRIC & MACHINERY MFG. CORP.	—	2	20,000	2,330	-	2,330	-
	CHINA WIRE & CABLE CO., LTD.	—	2	2,000	77	-	77	-
	Taiwan Fertilizer Co., Ltd.	—	2	2,000	135	-	135	-
	NANG KUANG PHARMACECUTICAL CO., LTD	—	2	4,000	213	-	213	-
	EVERGREEN STEEL CORPORATION	—	2	3,000	312	-	312	-
	United Microelectronics Corporation	—	2	7,000	368	-	368	-
	COMPEQ MANUFACTURING CO., LTD.	—	2	1,000	71	-	71	-
	TAIWAN SEMICONDUCTOR MANUFACTURING CO.,LTD.	—	2	1,000	593	-	593	-
	Synnex Technology International Corporation	—	2	1,000	70	-	70	-
	QUANTA COMPUTER INC.	—	2	1,000	225	-	225	-
	INSTEK ELECTRONIC (SHANGHAI) CO., LTD.	—	2	10,000	380	0.01%	380	-
	KING YUAN ELECTRONICS CO., LTD.	—	2	18,000	1,528	-	1,528	-
	UNIFORM INDUSTRIAL CORP. .	—	2	6,000	243	0.01%	243	-

Securities held by	Marketable securities	Relationship with the securities issuer	General ledger account	Number of shares	As of December 31, 2023			
					Book value	Ownership (%)	Fair value	Note
Advpharma Inc.	HANPIN ELECTRON CO., LTD.	—	2	1,000	\$ 40	-	\$ 40	-
	Goldsun Building Materials Co., Ltd.	—	2	1,000	28	-	28	-
	HUNG SHENG CONSTRUCTION CO., LTD.	—	2	3,000	61	-	61	-
	Taiwan Navigation Co., Ltd.	—	2	3,000	99	-	99	-
	EVA AIRWAYS CORPORATION	—	2	3,000	94	-	94	-
	Bafang Yunji International Co., Ltd.	—	2	1,000	171	-	171	-
	CHANG HWA COMMERCIAL BANK, LTD.	—	2	5,000	90	-	90	-
	Shinkong Insurance Co., Ltd.	—	2	3,000	204	-	204	-
	Yuanta Financial Holding Co., Ltd.	—	2	30,000	828	-	828	-
	SinoPac Financial Holdings Co., LTD.	—	2	20,000	394	-	394	-
	First Financial Holding Co.,Ltd.	—	2	47,000	1,288	-	1,288	-
	Zero One Technology Co., Ltd.	—	2	8,000	523	0.01%	523	-
	Unimicron Technology Corp.	—	2	1,000	176	-	176	-
	TXC CORPORATION	—	2	4,000	394	-	394	-
	POWERCOM CO., LTD.	—	2	4,000	148	0.01%	148	-
	ASX-ASE Technology Holding Co., Ltd.	—	2	1,000	135	-	135	-
	TOPKEY CORPORATION	—	2	1,000	179	-	179	-
	Primax Electronics Ltd.	—	2	2,000	135	-	135	-
	STAR COMGISTIC CAPITAL CO., LTD.	—	2	3,000	97	-	97	-
	GENERAL PLASTIC INDUSTRIAL CO., LTD.	—	2	1,000	35	-	35	-
	Radiant Opto-Electronics Corporation	—	2	5,000	665	-	665	-
	ATEN INTERNATIONAL CO., LTD.	—	2	3,000	241	-	241	-
	Taiwan Surface Mounting Technology Corp.	—	2	1,000	96	-	96	-
	Symtek Automation Asia Co., Ltd.	—	2	4,000	418	0.01%	418	-
	WINSTAR DISPLAY CO., LTD	—	2	3,000	88	-	88	-
	CHANG WAH ELECTROMATERIALS INC.	—	2	1,000	35	-	35	-
	Pou Chen Corporation	—	2	1,000	31	-	31	-
	TAIWAN SAKURA CORPORATION	—	2	3,000	209	-	209	-
	Yulon Finance Corporation	—	2	1,000	186	-	186	-
	Channel Well Technology Co., Ltd	—	2	2,000	168	-	168	-
	Ardentec Corporation	—	2	1,000	74	-	74	-
	Winstek Semiconductor Co., Ltd.	—	2	4,000	365	-	365	-
	AIC INC.	—	2	1,000	441	-	441	-
	TTY Biopharm Company Limited	—	2	3,000	241	-	241	-
	LEO SYSTEMS, INC.	—	2	1,000	34	-	34	-
	SIMPLO TECHNOLOGY CO., LTD.	—	2	6,000	2,520	-	2,520	-
	Chipbond Technology Corporation	—	2	13,000	940	-	940	-
	Quanta Storage Inc.	—	2	1,000	82	-	82	-
	CHANG WAH TECHNOLOGY CO., LTD.	—	2	1,000	33	-	33	-
	Ever Supreme Bio Technology Co., Ltd.	—	2	1,000	196	-	196	-
	AMPIRE CO., LTD.	—	2	1,000	39	-	39	-

Securities held by	Marketable securities	Relationship with the securities issuer	General ledger account	Number of shares	As of December 31, 2023			
					Book value	Ownership (%)	Fair value	Note
Advpharma Inc.	BON FAME CO., LTD.	—	2	1,000	\$ 91	-	\$ 91	-
	Xxentria Technology Materials Co., Ltd.	—	2	1,000	72	-	72	-
	Deyong Biological Technology Co., Ltd.	—	3	76,698	716	3.70%	716	-
	TaiwanJ Pharmaceuticals Co., Ltd.	—	3	25,203	372	0.03%	372	-
Syngen Biotech Co., Ltd.	Stocks:							
	NCKU Venture Capital Co., Ltd.	—	3	650,000	3,913	4.17%	3,913	-
SYN-TECH CHEM & PHARM CO., LTD.	Bonds with repurchase agreement:							
	Ta Ching Bills Finance Corporation.	—	1	—	294,475	-	294,475	-

Note 1: Marketable securities in the table refer to stocks, bonds, beneficiary certificates and other related derivative securities.

Note 2: The general ledger account is classified into the following four categories:

1. Cash and cash equivalents
2. Financial assets at fair value through profit or loss - current
3. Financial assets at fair value through profit or loss - non-current
4. Financial assets at fair value through other comprehensive income - non-current

Note 3: Foreign currencies were translated into New Taiwan Dollars with exchange rate as of December 31, 2023 as follows: USD: NTD 1:30.71.

STANDARD CHEM & PHARM. CO., LTD.

Significant inter-company transactions during the reporting period

For the year ended December 31, 2023

Table 3

Expressed in thousands of NTD

				Transaction			
Number (Note 2)	Company name	Counterparty	Relationship (Note 3)	General ledger account	Amount	Transaction terms	Percentage of consolidated total operating revenues or total assets (Note 4)
0	Standard Chem & Pharm. Co., Ltd.	Syngen Biotech Co., Ltd.	1	Purchases	\$ 68,237	1 ~ 4 month(s) after monthly billings.	1%
			1	Accounts payable	( 23,030)	—	—
		Souriree Biotech & Pharm. Co., Ltd.	1	Purchases	78,809	1 ~ 4 month(s) after monthly billings.	1%
			1	Accounts payable	( 13,266)	—	—
		SYN-TECH CHEM & PHARM CO., LTD.	1	Purchases	20,389	1 ~ 4 month(s) after monthly billings.	—
		Jiangsu Standard Biotech Pharmaceutical Co., Ltd.	1	Other expenses	13,696	1 ~ 4 month(s) after monthly billings.	—
		Ho Yao Biopharm Co., Ltd.	1	Other expenses	14,856	1 ~ 4 month(s) after monthly billings.	—
1	Standard Pharmaceutical Co., Ltd.	Jiangsu Standard Biotech Pharmaceutical Co., Ltd.	3	Other receivables	92,244	—	1%
		Standard Chem & Pharm. Co., Ltd.	2	Other expenses	22,845	30 days after monthly billings.	—
2	Syngen Biotech Co., Ltd.						
	SYN-TECH CHEM. & PHARM. CO., LTD.	Standard Chem & Pharm. Co., Ltd.	2	Lease Liabilities	15,021	—	—
3		Souriree Biotech & Pharm. Co., Ltd.	3	Sales	10,285	Receiving promissory note mature in 4 months at next month after sales, or receiving promissory note mature in 1~3 month(s) after sales	—

Note 1: As the amounts and counterparties of significant inter-company transactions are the same from the opposite transaction sides, no disclosure is required. Only transactions amounting to more than \$10,000 are disclosed.

Note 2: The numbers filled in for the transaction company in respect of inter-company transactions are as follows:

(1) Parent company is '0'.

(2) The subsidiaries are numbered in order starting from '1'.

Note 3: Relationship between transaction company and counterparty is classified into the following three categories:

(1) Parent company to subsidiary.

(2) Subsidiary to parent company.

(3) Subsidiary to subsidiary.

Note 4: Regarding percentage of transaction amount to consolidated total operating revenues or total assets, it is computed based on ending balance of transaction to consolidated total assets for balance sheet accounts and based on accumulated transaction amount for the year to consolidated total operating revenues for statement of comprehensive income accounts.

Note 5: Foreign currencies were translated into New Taiwan Dollars with exchange rate as of December 31, 2023 as follows: USD: NTD 1:30.71 and RMB: NTD 1:4.327.

STANDARD CHEM & PHARM. CO., LTD.

Information on investees

For the year ended December 31, 2023

Table 4

Expressed in thousands of NTD

Investor	Investee	Location	Main business activities	Initial investment amount		Shares held as at December 31, 2023			Net profit (loss) of the investee for the year ended December 31, 2023	Investment income (loss) recognised for the year ended December 31, 2023	Note
				Balance as at December 31, 2023	Balance as at December 31, 2022	Number of shares	Ownership (%)	Book value			
Standard Chem & Pharm. Co., Ltd.	Standard Pharmaceutical Co., Ltd.	Samoa	Research and development, trading, investment and other business of medical products	\$ 396,953	\$ 396,953	13,000,000	100.00	\$ 179,272	(\$ 1,618)	(\$ 1,618)	Subsidiary
	Chia Scheng International Co., Ltd.	Taiwan	General investment	161,356	161,356	14,553,000	100.00	11,363	266	266	Subsidiary (Note 1)
	STANDARD CHEM. & PHARM. PHILIPPINES, INC.	Philippines	Import and export of various medical products, medicine, supplements	12,340	6,762	392,014	100.00	3,996	( 1,883)	( 1,883)	Subsidiary
	Inforight Technology Co., Ltd.	Taiwan	Wholesale of multi-function printers and information software	5,000	5,000	500,000	100.00	7,666	3,454	3,454	Subsidiary
	Souriree Biotech & Pharm. Co., Ltd.	Taiwan	Manufacturing of western medicine and retail and wholesale of various medicines	41,871	41,871	5,673,908	93.58	50,404	9,402	8,965	Subsidiary
	Multipower Enterprise Corp.	Taiwan	Import and export of western medicine, nourishment and function food, processing, manufacturing and sale of food	293,063	293,063	19,840,600	90.72	324,570	( 13,971)	( 12,827)	Subsidiary
	Advpharma Inc.	Taiwan	Research and development, manufacturing and sale of various medicine	525,933	525,933	53,226,806	88.71	271,699	5,460	4,908	Subsidiary
	Syngen Biotech Co., Ltd.	Taiwan	Research and development, manufacturing and sale of APIs, biopesticide, fertiliser and biochemical nutrition, sale of preventive medicine	330,203	330,203	12,651,146	46.68	975,993	274,827	128,862	Subsidiary (Note 2)
	SYN-TECH CHEM. & PHARM. CO., LTD.	Taiwan	Manufacturing and sale of APIs, reagent, surfactant, Chinese, western, and veterinary medicinal products	720,941	720,941	12,675,959	28.43	784,589	251,150	63,757	Subsidiary (Note 3)
	Ho Yao Biopharm Co., LTD.	Taiwan	Research and development of new medicine	46,800	46,800	3,680,000	84.99	43,286	5,730	4,869	Subsidiary

Investor	Investee	Location	Main business activities	Initial investment amount		Shares held as at December 31, 2023			Net profit (loss) of the investee for the year ended December 31, 2023	Investment income (loss) recognised for the year ended December 31, 2023	Note
				Balance as at December 31, 2023	Balance as at December 31, 2022	Number of shares	Ownership (%)	Book value			
Standard Chem & Pharm. Co., Ltd.	WE CAN MEDICINES CO., LTD.	Taiwan	Wholesale of various medicine	\$ 277,067	\$ 277,067	13,155,909	32.89	\$ 243,423	\$ 14,803	\$ 4,679	Associate
	Taiwan Biosim, Co., Ltd.	Taiwan	Research and development of various medicine	49,900	49,900	4,990,000	49.90	32,776	1,591	794	Associate
Syngen Biotech Co., Ltd	SYNGEN BIOTECH INTERNATIONAL SDN. BHD.	Malaysia	Research and development, manufacturing and sale of APIs and biochemical nutrition, sale of preventive medicine	14,064	7,322	2,000,000	100.00	6,851	( 791)	-	Subsidiary (Note 4)
	Jhan Shuo Biopharma Co., Ltd.	Taiwan	Manufacturing, wholesale and sale of western medicine	100	100	10,000	100.00	101	1	-	Subsidiary (Note 4)
	GENEFERM BIOTECHNOLOGY CO., LTD.	Taiwan	Research and development, design, quantification, manufacturing and sale of microbial and edible mushroom medicine fermentation, herbal and vegetal functional products, fruit and vegetable fermentation concentrates and protein products, management of the aforementioned trade business, technological consultancy, etc.	273,840	273,840	12,000,000	28.94	327,830	124,621	-	Associate (Note 4)
Advpharma Inc.	CNH TECHNOLOGIES INC.	USA	Research and development of various medicine	13,734	13,734	400,000	35.60	1,202	1,478	-	(Note 4)
SYN-TECH CHEM. & PHARM. CO., LTD.	Advpharma Inc.	Taiwan	Research and development, manufacturing and sale of various medicine	9,626	9,626	1,495,414	2.49	7,823	5,460	-	(Note 4)
	CNH TECHNOLOGIES INC.	USA	Research and development of various medicine	21,092	21,092	535,050	47.62	1,834	1,478	-	(Note 4)

Note 1: Formerly named as ‘Chia Scheng Investment Co., Ltd.’ and the name was changed since October 12, 2023.

Note 2: In September 2016, the subsidiary, Syngen Biotech Co., Ltd. ("Syngen"), filed for an initial public offering with Taipei Exchange. As part of the public trading process, the Company allowed its underwriter to exercise the overallotment option, which decreased the Company's ownership percentage in Syngen to below 50%. However, the Company did not lose control over Syngen.

Note 3: The company participated in the cash capital increase of SYN-TECH CHEM. & PHARM. CO., LTD., which results in becoming SYN-TECH's single largest corporate shareholder and having substantial control over it.

Note 4: Not required to disclose income (loss) recognised.

Note 5: Foreign currencies were translated into New Taiwan Dollars with exchange rate as of December 31, 2023 as follows: USD: NTD 1:30.71.

STANDARD CHEM & PHARM. CO., LTD.  
Information on investments in Mainland China  
For the year ended December 31, 2023

Table 5

Expressed in thousands of NTD

Investee in Mainland China	Main business activities	Paid-in capital	Investment method	Accumulated amount of remittance from Taiwan to Mainland	Amount remitted from Taiwan to Mainland China/Amount remitted back to Taiwan for the year ended December 31, 2023		Accumulated amount of remittance from Taiwan to Mainland China as of December 31, 2023	Net income (loss) of investee for the year ended December 31, 2023	Ownership held by the Company (direct or indirect)	Investment income (loss) recognised for the year ended December 31, 2023	Book value of investments in Mainland China as of December 31, 2023	Accumulated amount of investment income remitted back to Taiwan as of December 31, 2023	Note
				China as of January 1, 2023	Remitted to Mainland China	Remitted back to Taiwan							
Jiangsu Standard Biotech Pharmaceutical Co., Ltd.	Research and development, technical consulting and technical services of medicine	\$ 276,390	(Note 1)	\$ 276,084	\$ -	\$ -	\$ 276,084	(\$ 3,278)	100.00	(\$ 3,278)	\$ 48,240	\$ -	(Note 4)
Jiangsu Standard-Dia Biopharma Co., Ltd.	Research and development, manufacturing and sale of various medicine	183,444	(Note 2)	-	-	-	-	( 9,265)	55.00	( 4,962)	( 11,326)	-	(Note 4)
Shanghai Standard Pharmaceuticals Co., Ltd.	Sale of various medicine and dietary supplement	4,512	(Note 3)	4,512	-	-	4,512	( 1,958)	100.00	( 1,958)	1,285	-	(Note 4)

Company name	Accumulated amount of remittance from Taiwan to Mainland China as of December 31, 2023	Investment amount approved by the Investment Commission of the Ministry of Economic Affairs (MOEA)	Ceiling on investments in Mainland China imposed by the Investment Commission of MOEA
		(Note 5)	(Note 5)
Standard Chem & Pharm. Co., Ltd.	\$ 280,596	\$ 280,901	\$ 4,882,402

Note 1: Indirect investment in Mainland China through an existing company (Standard Pharmaceutical Co., Ltd.) located in the third area.

Note 2: Indirect investment in Mainland China through an existing company (Jiangsu Standard Biotech Pharmaceutical Co., Ltd.) located in Mainland China.

Note 3: Direct investment in Mainland China from Taiwan.

Note 4: Recognition is based on investees' financial statements audited and attested by independent accountants.

Note 5: Ceiling is the higher of net assets or 60% of consolidated equity.

Note 6: Foreign currencies were translated into New Taiwan Dollars with exchange rate as of December 31, 2023 as follows: USD: NTD 1:30.71 and RMB: NTD 1:4.327.



STANDARD CHEM & PHARM. CO., LTD.  
Major Shareholders Information  
December 31, 2023

Table 6

Major Shareholder's Name	Shares	
	Number of shares	Percentage
Chin-Tsai, Fan	20,636,813	12%
Tzu-Pin, Fan	19,518,084	11%
Mei-Rong, Fan Hung	14,584,781	8%
Tzu-Tin, Fan	11,766,604	7%
Sen-Hao, Cheng	9,185,888	5%
Tsuey-Wen, Yeh	9,124,669	5%

Note 1: The information of major shareholders in this table is calculated by TDCC on the last business day at the end of each quarter to calculate that the shareholder-holding company has completed the book-entry delivery (including treasury stocks) of common stocks and special stocks totaling more than 5%. As for the share capital recorded in the company's financial report and the company's actual number of shares registered and delivered may be different due to the calculation bases.

Note 2: If shareholder has his/hers shares been entrusted, it shall disclosed in the trustee's individual accounts. As for shareholder's declaration of shares held by insiders with more than 10%, for shareholding that includes shares on hand and those have been entrusted, and the right to their entrust property, etc., please refer to MOPS's website.

STANDARD CHEM. & PHARM. CO., LTD.  
STATEMENT OF CASH AND CASH EQUIVALENTS  
DECEMBER 31, 2023  
 (EXPRESSED IN THOUSANDS OF NEW TAIWAN DOLLARS)

Item	Description	Amount
Cash:		
Revolving funds and petty cash		\$ 8,542
Demand deposits-New Taiwan Dollar		177,466
-Foreign currency	Including JPY 65,404 thousand @0.2172	14,206
	USD 1,102 thousand @30.71	33,852
	CNY 2,446 thousand @4.327	10,583
	EUR 0.2 thousand @33.98	8
Cash equivalents:		
Time deposits-Foreign currency	Including CNY 1,000 thousand @4.327 due on 2024/01/12, interest rate at 1.35%	4,327
	Including USD 14,600 thousand @30.71 due on 2024/01/08~2024/03/22, interest rate at 5.13% ~ 5.65%	448,366
Repurchase bonds-Foreign currency	Including USD 600 thousand @30.71 due on 2024/01/16, interest rate at 5.60%	18,424
		<u>\$ 715,774</u>

STANDARD CHEM. & PHARM. CO., LTD.  
STATEMENT OF NOTES RECEIVABLE  
DECEMBER 31, 2023  
 (EXPRESSED IN THOUSANDS OF NEW TAIWAN DOLLARS)

Client Name	Description	Amount	Note
Non-related parties:			
Others (individually less than 5%)	Notes receivable	\$ 104,686	—
Related parties:			
SUN YOU BIOTECH PHARM CO., LTD.	Notes receivable	2,773	—
Souriree Biotech & Pharm. Co., Ltd.	Notes receivable	909	—
Syngen Biotech Co., Ltd.	Notes receivable	687	—
		4,369	
		<u>\$ 109,055</u>	

STANDARD CHEM. & PHARM. CO., LTD.  
STATEMENT OF ACCOUNTS RECEIVABLE (NET)  
DECEMBER 31, 2023  
 (EXPRESSED IN THOUSANDS OF NEW TAIWAN DOLLARS)

Client Name	Description	Amount	Note
Non-related parties:			
Company A	Accounts receivable	\$ 161,492	—
Others (individually less than 5%)	Accounts receivable	413,901	—
		575,393	
Less: Allowance for doubtful accounts		( 4,537)	—
		570,856	
Related parties:			
SUN YOU BIOTECH PHARM CO., LTD.	Accounts receivable	4,085	—
WE CAN MEDICINES CO., LTD.	Accounts receivable	2,576	—
STANDARD CHEM. & PHARM. PHILLIPPINES, INC.	Accounts receivable	878	—
Syngen Biotech Co., Ltd.	Accounts receivable	10	—
		7,549	
		<u>\$ 578,405</u>	

STANDARD CHEM. & PHARM. CO., LTD.  
STATEMENT OF INVENTORIES  
DECEMBER 31, 2023  
 (EXPRESSED IN THOUSANDS OF NEW TAIWAN DOLLARS)

Item	Description	Amount		Note
		Cost	Net Realisable Value	
Merchandise	—	\$ 49,060	\$ 83,204	(Note)
Raw materials	—	225,052	220,234	(Note)
Supplies	—	42,447	41,694	(Note)
Work in progress	—	75,717	75,717	(Note)
Finished goods	—	328,267	675,702	(Note)
		720,543	<u>\$ 1,096,551</u>	
Less: Allowance for inventory valuation losses		( 16,389)		
		<u>\$ 704,154</u>		

(Note) Refer to Note 4(10) for the method to determine the net realisable value.

STANDARD CHEM. & PHARM. CO., LTD.  
STATEMENT OF CHANGES IN FINANCIAL ASSETS MEASURED AT FAIR VALUE THROUGH OTHER COMPREHENSIVE INCOME - NON-  
CURRENT

FOR THE YEAR ENDED DECEMBER 31, 2023

(Expressed in thousands of New Taiwan dollars, except as otherwise indicated)

Name	Beginning Balance		Addition		Decrease		Valuation	Ending Balance		Collateral	Note
	Shares (in thousands)	Fair Value	Shares (in thousands)	Amount	Shares (in thousands)	Amount	Adjustments Amount	Shares (in thousands)	Fair Value		
Listed stocks:											
Rossmax International Ltd.	2,990	\$ 73,106	814	\$ 18,983	( 2,500)	(\$ 53,499)	(\$ 5,990)	1,304	\$ 32,600	None	—
EASYWELL BIOMEDICALS, INC.	5,095	81,768	—	—	—	—	128,639	5,095	210,407	None	—
Unlisted stocks:											
HER-SING CO., LTD.	3,055	42,770	—	—	—	—	6,049	3,055	48,819	None	—
SUN YOU BIOTECH PHARM CO., LTD.	3,378	44,421	—	—	—	—	1,317	3,378	45,738	None	—
Green Management International Co., Ltd.	110	1,751	—	—	—	—	122	110	1,873	None	—
Kenda Pharmaceutical Co., Ltd.	5,000	4,550	—	—	—	—	( 150)	5,000	4,400	None	—
		<u>\$ 248,366</u>		<u>\$ 18,983</u>		<u>(\$ 53,499)</u>	<u>\$ 129,987</u>		<u>\$ 343,837</u>		

STANDARD CHEM. & PHARM. CO., LTD.  
STATEMENT OF CHANGES IN INVESTMENTS ACCOUNTED FOR UNDER EQUITY METHOD  
FOR THE YEAR ENDED DECEMBER 31, 2023  
(EXPRESSED IN THOUSANDS OF NEW TAIWAN DOLLARS)

Name	Beginning Balance		Additions		Decrease		Ending Balance			Market Value or Net Assets Value			
	Shares	Amount	Shares	Amount	Shares	Amount	Shares	Percentage of		Unit Price	Total Amount	Collateral	Note
	(in thousands)		(in thousands)		(in thousands)		(in thousands)	Ownership	Amount				
Standard Pharmaceutical Co., Ltd.	13, 000	\$ 181, 720	-	\$ 12, 061	-	(\$ 14, 509)	13, 000	100%	\$ 179, 272	\$ 13. 79	\$ 179, 272	None	—
Chia Scheng International Co., Ltd.(Note)	14, 553	11, 003	-	413	-	( 53)	14, 553	100%	11, 363	0. 78	11, 363	None	—
Standard CHEM. & PHARM. PHILIPPINES, INC.	192	314	200	5, 656	-	( 1, 974)	392	100%	3, 996	10. 19	3, 996	None	—
Inforight Technology Co., Ltd.	500	4, 212	-	3, 454	-	-	500	100%	7, 666	15. 33	7, 666	None	—
Souriree Biotech & Pharm. Co., Ltd.	5, 674	41, 483	-	10, 899	-	( 1, 978)	5, 674	93. 58%	50, 404	14. 17	80, 400	None	—
Multipower Enterprise Corp.	19, 841	337, 397	-	-	-	( 12, 827)	19, 841	90. 72%	324, 570	12. 93	256, 499	None	—
Advpharma Inc.	53, 227	266, 798	-	5, 169	-	( 268)	53, 227	88. 71%	271, 699	5. 23	278, 446	None	—
Syngen Biotech Co., Ltd.	12, 651	910, 035	-	130, 116	-	( 64, 158)	12, 651	46. 68%	975, 993	152. 00	1, 922, 800	None	—
SYN-TECH CHEM. & PHARM. CO., LTD.	12, 676	758, 751	-	67, 521	-	( 41, 683)	12, 676	28. 43%	784, 589	85. 20	1, 079, 995	None	—
Ho Yao Biopharm Co., Ltd.	3, 680	38, 417	-	6, 466	-	( 1, 597)	3, 680	84. 99%	43, 286	8. 59	31, 608	None	—
Shanghai Shengda Zhengcheng Pharmaceutical Co., Ltd.	-	3, 274	-	361	-	( 2, 350)	-	100. 00%	1, 285	-	1, 285	None	—
WE CAN MEDICINES CO., LTD.	13, 156	235, 502	-	7, 921	-	-	13, 156	32. 89%	243, 423	108. 00	1, 420, 848	None	—
Taiwan Biosim Co., Ltd.	4, 990	<u>31, 982</u>	-	<u>1, 933</u>	-	( <u>1, 139</u> )	4, 990	49. 90%	<u>32, 776</u>	6. 57	<u>32, 776</u>	None	—
		<u>\$ 2, 820, 888</u>		<u>\$ 251, 970</u>		<u>(\$ 142, 536)</u>			<u>\$2, 930, 322</u>		<u>\$5, 306, 954</u>		

(Note) Formerly named as 'Chia Scheng Investment Co., Ltd.' and the name was changed since October 12, 2023.

STANDARD CHEM. & PHARM. CO., LTD.  
STATEMENT OF CHANGES IN COST OF PROPERTY, PLANT AND EQUIPMENT  
FOR THE YEAR ENDED DECEMBER 31, 2023  
(EXPRESSED IN THOUSANDS OF NEW TAIWAN DOLLARS)

Refer to Note 6(8) for the information related to property, plant and equipment.



STANDARD CHEM. & PHARM. CO., LTD.  
STATEMENT OF CHANGES IN ACCUMULATED DEPRECIATION OF PROPERTY, PLANT AND  
EQUIPMENT  
FOR THE YEAR ENDED DECEMBER 31, 2023  
(EXPRESSED IN THOUSANDS OF NEW TAIWAN DOLLARS)

Refer to Note 6(8) for the information related to property, plant and equipment and  
Note 4(15) for the method to determine depreciation and useful lives for assets.

STANDARD CHEM. & PHARM. CO., LTD.  
STATEMENT OF CHANGES IN COST OF INVESTMENT PROPERTY  
FOR THE YEAR ENDED DECEMBER 31, 2023  
(EXPRESSED IN THOUSANDS OF NEW TAIWAN DOLLARS)

Refer to Note 6(10) for the information related to investment property.

STANDARD CHEM. & PHARM. CO., LTD.  
STATEMENT OF CHANGES IN ACCUMULATED DEPRECIATION OF INVESTMENT PROPERTY  
FOR THE YEAR ENDED DECEMBER 31, 2023  
(EXPRESSED IN THOUSANDS OF NEW TAIWAN DOLLARS)

Refer to Note 6(10) for the information related to investment property and  
Note 4(17) for the method to determine depreciation and useful lives for.

STANDARD CHEM. & PHARM. CO., LTD.  
STATEMENT OF CHANGES IN DEFERRED TAX ASSETS  
FOR THE YEAR ENDED DECEMBER 31, 2023  
(EXPRESSED IN THOUSANDS OF NEW TAIWAN DOLLARS)

Refer to Note 6(25) for the information related to income tax.

STANDARD CHEM. & PHARM. CO., LTD.  
STATEMENT OF GUARANTEE DEPOSITS PAID  
DECEMBER 31, 2023  
 (EXPRESSED IN THOUSANDS OF NEW TAIWAN DOLLARS)

Client Name	Description	Amount	Note
Company B	Performance guarantee	\$ 10,523	—
Company C	Performance guarantee	7,493	—
Company D	Performance guarantee	6,134	—
Company E	Performance guarantee	3,740	—
Company F	Performance guarantee	2,770	—
Others (individually less than 5%)	Performance guarantee,	7,631	—
	Lease deposit and bid bond		
		<u>\$ 38,291</u>	

STANDARD CHEM. & PHARM. CO., LTD.  
STATEMENT OF SHORT-TERM BORROWINGS  
DECEMBER 31, 2023  
 (EXPRESSED IN THOUSANDS OF NEW TAIWAN DOLLARS)

Nature	Description	Ending Balance	Contract Period	Interest Rate	Credit Line	Collateral
Unsecured bank borrowings	Citibank Taiwan Ltd.	\$ 210,000	2023.11.21~2024.02.19	1.58%	USD 7,000 thousand	None
	Yuanta Commercial Bank Co., Ltd.	100,000	2023.12.12~2024.02.22	1.66%	300,000	None
	Taishin International Bank	60,000	2023.10.26~2024.01.24	1.66%	100,000	None
	Yuanta Commercial Bank Co., Ltd.	50,000	2023.11.24~2024.02.22	1.66%	300,000	None
	Taishin International Bank	30,000	2023.10.16~2024.01.12	1.66%	100,000	None
	Taishin International Bank	10,000	2023.11.09~2024.02.07	1.66%	100,000	None
		<u>\$ 460,000</u>				

STANDARD CHEM. & PHARM. CO., LTD.  
STATEMENT OF CONTRACT LIABILITIES - CURRENT  
DECEMBER 31, 2023  
 (EXPRESSED IN THOUSANDS OF NEW TAIWAN DOLLARS)

Client Name	Description	Amount	Note
Company A	Advance sales receipts	\$ 6, 056	—
Company B	Advance sales receipts	2, 930	—
Others (Individually less than 5%)	Advance sales receipts	25, 913	—
		<u>\$ 34, 899</u>	

STANDARD CHEM. & PHARM. CO., LTD.  
STATEMENT OF NOTES PAYABLE  
DECEMBER 31, 2023  
 (EXPRESSED IN THOUSANDS OF NEW TAIWAN DOLLARS)

Client Name	Description	Amount	Note
Company C	Notes payable	\$ 12,311	—
Company D	Notes payable	8,385	—
Others (individually less than 5%)	Notes payable	113,620	—
		<u>\$ 134,316</u>	



STANDARD CHEM. & PHARM. CO., LTD.  
STATEMENT OF ACCOUNTS PAYABLE  
DECEMBER 31, 2023  
(EXPRESSED IN THOUSANDS OF NEW TAIWAN DOLLARS)

Client Name	Description	Amount	Note
Non-related parties:			
Company E	Accounts payable	\$ 13,582	—
Company F	Accounts payable	9,261	—
Company G	Accounts payable	6,706	—
Others (individually less than 5%)	Accounts payable	92,122	—
		<u>121,671</u>	
Related parties:			
Syngen Biotech Co., Ltd.	Accounts payable	23,030	—
Souriree Biotech & Pharm. Co., Ltd.	Accounts payable	13,266	—
Syn-Tech Chem & Pharm Co., Ltd.	Accounts payable	6,525	—
Sun You Biotech Pharm Co., Ltd.	Accounts payable	2,268	—
		<u>45,089</u>	
		<u>\$ 166,760</u>	

STANDARD CHEM. & PHARM. CO., LTD.  
STATEMENT OF OTHER PAYABLES  
DECEMBER 31, 2023  
 (EXPRESSED IN THOUSANDS OF NEW TAIWAN DOLLARS)

Item	Description	Amount	Note
Wages and salaries payable	—	\$ 117,595	—
Provision for employee benefits	—	26,853	—
Employees' compensation and directors' remuneration payable	—	22,207	—
Others (individually less than 5%)	—	86,042	—
		<u>\$ 252,697</u>	

STANDARD CHEM. & PHARM. CO., LTD.  
STATEMENT OF INCOME TAX LIABILITIES  
DECEMBER 31, 2023  
 (EXPRESSED IN THOUSANDS OF NEW TAIWAN DOLLARS)

Item	Description	Amount	Note
Corporate income tax payable	—	\$ 96,261	—
Tax payable on undistributed earnings	—	12,260	—
		<u>\$ 108,521</u>	

STANDARD CHEM. & PHARM. CO., LTD.  
STATEMENT OF CHANGES IN DEFERRED TAX LIABILITIES  
FOR THE YEAR ENDED DECEMBER 31, 2023  
(EXPRESSED IN THOUSANDS OF NEW TAIWAN DOLLARS)

Refer to Note 6(25) for the information related to income tax.

STANDARD CHEM. & PHARM. CO., LTD.  
STATEMENT OF CHANGES IN NET DEFINED BENEFIT LIABILITY - NON-CURRENT  
FOR THE YEAR ENDED DECEMBER 31, 2023  
(EXPRESSED IN THOUSANDS OF NEW TAIWAN DOLLARS)

Refer to Note 6(13) for the information related to pensions.

STANDARD CHEM. & PHARM. CO., LTD.  
STATEMENT OF OPERATING REVENUE  
FOR THE YEAR ENDED DECEMBER 31, 2023  
(EXPRESSED IN THOUSANDS OF NEW TAIWAN DOLLARS)

Item	Volume	Subtotal	Total	Note
Medicine:				
Troche	1,436,637 thousand	\$ 2,034,706		—
Ampoule	9,101 thousand	270,681		—
Capsule	145,365 thousand	261,264		—
Liquids	817,714 L	320,609		—
Others		<u>213,257</u>	\$ 3,100,517	—
Dietary supplement			129,680	—
Others			<u>4,749</u>	—
			3,234,946	
Less: Sales returns, discounts and allowances			( <u>245,311</u> )	—
Operating revenue			<u>\$ 2,989,635</u>	

STANDARD CHEM. & PHARM. CO., LTD.  
STATEMENT OF OPERATING COSTS  
FOR THE YEAR ENDED DECEMBER 31, 2023  
 (EXPRESSED IN THOUSANDS OF NEW TAIWAN DOLLARS)

Item	Amount
Merchandise at January 1, 2023	\$ 48,366
Add : Merchandise purchased	178,716
Less : Transferred to expenses	( 1,007)
Scrapped	( 300)
Merchandise at December 31, 2023	( 49,060)
Merchandise sold during the year	<u>176,715</u>
Raw materials at January 1, 2023	185,304
Add : Raw materials purchased	623,065
Work in process transfer in	421
Supplies transfer in	20
Gain on physical inventory	573
Less : Transferred to expenses	( 3,072)
Scrapped	( 1,709)
Raw materials sold	( 2)
Raw materials at December 31, 2023	( 225,052)
Raw materials used during the year	<u>579,548</u>
Supplies at January 1, 2023	37,174
Add : Supplies purchased	219,853
Gain on physical inventory	416
Less : Transferred to expenses	( 3,111)
Transferred to raw materials	( 20)
Scrapped	( 1,060)
Supplies sold	( 2)
Supplies at December 31, 2023	( 42,447)
Supplies used during the year	<u>210,803</u>
Direct labour	<u>175,670</u>
Manufacturing overhead	<u>455,148</u>
Manufacturing cost	1,421,169

STANDARD CHEM. & PHARM. CO., LTD.  
STATEMENT OF OPERATING COSTS (CONTINUED)  
FOR THE YEAR ENDED DECEMBER 31, 2023  
 (EXPRESSED IN THOUSANDS OF NEW TAIWAN DOLLARS)

Item	Amount
Work in process at January 1, 2023	\$ 76,836
Less: Transferred to expenses	( 870)
Transferred to raw materials	( 421)
Loss on physical inventory	( 4)
Scrapped	( 3,490)
Work in process at December 31, 2023	( 75,717)
Cost of finished goods	1,417,503
Finished goods at January 1, 2023	227,347
Less: Transferred to expenses	( 5,387)
Scrapped	( 4,056)
Finished goods at December 31, 2023	( 328,267)
Cost of production and marketing	1,307,140
Cost of finished goods sold	1,483,855
Cost of raw materials sold	2
Cost of supplies sold	2
Cost of inventory sold	1,483,859
Losses on scrapped inventory	10,615
Provision for inventory market price decline	3,760
Gain on physical inventory	( 985)
Operating costs	\$ 1,497,249



STANDARD CHEM. & PHARM. CO., LTD.  
STATEMENT OF MANUFACTURING OVERHEAD  
FOR THE YEAR ENDED DECEMBER 31, 2023  
 (EXPRESSED IN THOUSANDS OF NEW TAIWAN DOLLARS)

Item	Description	Amount	Note
Wages and salaries	—	\$ 166,805	—
Depreciation	—	74,415	—
Utilities	—	38,460	—
Repair and maintenance	—	23,228	—
Others (individually less than 5%)	—	152,240	—
		<u>\$ 455,148</u>	

STANDARD CHEM. & PHARM. CO., LTD.  
STATEMENT OF SELLING EXPENSES  
FOR THE YEAR ENDED DECEMBER 31, 2023  
 (EXPRESSED IN THOUSANDS OF NEW TAIWAN DOLLARS)

Item	Description	Amount	Note
Wages and salaries	—	\$ 229, 511	—
Commission	—	63, 461	—
Travel expenses	—	29, 030	—
Others (individually less than 5%)	—	136, 438	—
		<u>\$ 458, 440</u>	

STANDARD CHEM. & PHARM. CO., LTD.  
STATEMENT OF ADMINISTRATIVE EXPENSES  
FOR THE YEAR ENDED DECEMBER 31, 2023  
 (EXPRESSED IN THOUSANDS OF NEW TAIWAN DOLLARS)

Item	Description	Amount	Note
Wages and salaries	—	\$ 101,950	—
Insurance	—	16,108	—
Professional service fees	—	15,574	—
Others (individually less than 5%)	—	52,608	—
		<u>\$ 186,240</u>	

STANDARD CHEM. & PHARM. CO., LTD.  
STATEMENT OF RESEARCH AND DEVELOPMENT EXPENSES  
FOR THE YEAR ENDED DECEMBER 31, 2023  
 (EXPRESSED IN THOUSANDS OF NEW TAIWAN DOLLARS)

Item	Description	Amount	Note
Wages and salaries	—	\$ 55,127	—
Research expenses	—	96,589	—
Depreciation	—	12,053	—
Others (individually less than 5%)	—	25,336	—
		<u>\$ 189,105</u>	

STANDARD CHEM. & PHARM. CO., LTD.  
STATEMENT OF OTHER INCOME  
FOR THE YEAR ENDED DECEMBER 31, 2023  
(EXPRESSED IN THOUSANDS OF NEW TAIWAN DOLLARS)

Refer to Note 6(20) for the information related to other income.

STANDARD CHEM. & PHARM. CO., LTD.  
STATEMENT OF SUMMARY OF EMPLOYEE BENEFITS, DEPRECIATION, AND  
AMORTIZATION EXPENSES IN CURRENT PERIOD  
FOR THE YEAR ENDED DECEMBER 31, 2023  
(EXPRESSED IN THOUSANDS OF NEW TAIWAN DOLLARS)

Refer to Note 6(23) for the additional information related to expenses  
and Note 6(24) for the information related to employee benefits.